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ABSTRACT 
 CHARACTERISATION AND ANTIMICROBIAL SUSCEPTIBILITY 
PATTERN OF NON FERMENTING GRAM NEGATIVE BACILLI AND 
MOLECULAR ANALYSIS OF ACINETOBACTER SPP., FROM VARIOUS 
CLINICAL SAMPLES IN A TERTIARY CARE HOSPITAL 
BACKGROUND: 
 Non fermenting Gram Negative Bacilli (NFGNB) once considered as 
contaminants have now emerged as a major cause of life threatening nosocomial 
infections and as multidrug resistant pathogens. 
AIM: 
 To isolate and identify the NFGNB and their antimicrobial susceptibility 
pattern and to detect the Carbapenem resistant (Oxacillinase`and Metallo Beta 
Lactamase) Acinetobacter species by phenotypic and genotypic methods. 
Materials and Methods: 
 This Cross sectional study conducted in Chengalpattu Medical College 
and Hospital for one year and samples collected like pus, urine, endotracheal 
aspirates, blood, sputum and body fluids were identified using standard protocol, 
which includes Grams staining, test for motility, catalase test, oxidase test,  OF test 
and various biochemical reactions. The resistant strains of Acinetobacter species are 
subjected to molecular analysis of OXA-51, VIM and IMP genes. 
 
Results: 
 Out of 110 clinically significant isolates of nonfermenters,54(49%) were 
Pseudomonas aeruginosa, 36(32.7%) Acinetobacter baumannii,  8 (7.3%) 
Acinetobacter lwoffi, 6 (5.4%) S.maltophilia, and Pseudomonas stutzeri and 
Burkholderia cepecia 3(2.8%). The antimicrobial susceptibility pattern revealed 
maximum resistance to Gentamycin (61.8%), Cotrimoxazole (60%), followed by 
Ciprofloxacin(50.9%) and Cefotaxime (47.3%).Sensitivity to Polymyxin B (100%) 
followed by Imipenem and Meropenem (75.5%). ESBL production was 18.18 % and 
MBL production was 20.5%. Molecular characterization of  MBL of Acinetobacter 
species revealed ,OXA-51 (33.3%),  3 (33.3%) for bla IMP. and 2(22.2%) isolates 
bla VIM  positive . 
CONCLUSION: 
 Pseudomonas aeruginosa and Acinetobacter baumannii were the most 
common NFGNB isolated in this study. Difference in antimicrobial susceptibility by 
nonfermenters pose a great problem in treating these infections. ESBL and MBL 
production by these organisms lead to high morbidity and mortality and left with the 
only option of treating them by potentially toxic drugs like Colistin and  
Polymyxin B.  
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INTRODUCTION 
 Non fermenting Gram Negative Bacilli (NFGNB) are aerobic, non-spore 
forming  organisms  that  either  do  not  use  carbohydrates  as  a  source  of  energy  (or)  
degrade them through metabolic pathways other than fermentation (1,2,3). 
         These bacteria occur as saprophytes in the environment and also found as 
commensals in the human gut (2). These are ubiquitous in nature particularly in soil 
and water. Although frequently considered as contaminants, most of them have 
emerged as important nosocomial pathogens causing opportunistic infections in 
immunocompromised hosts. NFGNB are known to account for about 15% of all 
bacterial isolates from a clinical microbiology laboratory (3). 
         Non fermenting Gram Negative Bacilli cause various infections including 
wound infections, urinary tract infections, meningitis, pneumonia, septicaemia, 
osteomyelitis, etc.,(4) Risk factors includes immunosuppression, neutropenia, 
mechanical ventilation, cystic fibrosis, indwelling catheters, invasive diagnostics 
and therapeutic procedures. They are recovered with increasing frequency from 
clinical specimens. Prolonged hospital stay, broad spectrum antibiotic use and 
underlying host factors are best predictors of out come (5). 
        This group includes organisms from diverse genera like Pseudomonas, 
Acinetobacter, Stenotrophomonas, Burkholderia, Alcaligenes, Weeksella, etc., 
currently; Pseudomonas aeruginosa and Acinetobacter baumanii are the most 
commonly isolated nonfermenters pathogenic for humans whereas infections caused 
by other species are relatively infrequent (3). 
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         In the National Nosocomial Infection Surveillance (NNIS) survey from 
the Centres for Disease Control and Prevention (CDC), Infections caused by 
nonfermenters is the fourth most common cause of nosocomial infection and leading 
cause of hospital acquired infections. Also it is the most common cause of wound 
infection among Gram negative bacteria with an isolation rate of up to 62% (6). 
Urinary tract infections caused by nonfermenters are mostly hospital acquired and 
isolations range from 12%-30%. It causes life threatening bacteremia especially in 
intensive  care  settings  at  a  rate  of  10%.   Ps. aeruginosa is the leading cause of 
pneumonia in the ICU patients with a mortality of 80 -100% (7). 
         Acinetobacter species are the opportunistic pathogens with increasing 
prevalance in the nosocomial infections (8).  Community acquired infections are also 
common in Acinetobacter. It accounts for 10% of all community-acquired 
bacteremic pneumonias (9).        
         Acinetobacter spp., have been reported to cause high mortality rate of 
32% to 52% in blood stream infections. Similarly mortality rate upto 70% have been 
reported in ICU acquired pneumonias (9).  Hence  the  identification  of  Acinetobacter 
spp., from clinical specimens is very essential. 
          Members of non fermenting gram negative bacteria show resistance to a 
wide range of commonly used antibiotics by several mechanisms like antimicrobial 
inactivating enzymes, reduced access to bacterial targets and point mutations that 
change targets or cellular functions (10). The antimicrobial inactivating enzymes are 
beta lactamases including Extended Spectrum Betalactamases (ESBL), AmpC, Non-
metallo beta lactamases and Metallo betalactamases (MBL) (11).  Resistance  to  
carbapenams in nonfermenters can be intrinsic or acquired. Intrinsic resistance is 
seen in S.maltophilia while acquired Class B metallobetalactamases (MBL) and 
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class D serine carbapenamases are frequently found in Ps.aeruginosa and 
Acinetobacter respectively.  These  acquired  MBL  genes  (IMP,  VIM,  SPM,  GIM  
types)  are  usually  clustered  with  other  resistance  determinants  on  mobile  DNA  
elements and their presence is virtually constant marker for multidrug résistance. 
Multidrug resistance (MDR) exhibited by nonfermenters pose a major clinical 
problem in treating infections caused by them. Therefore early identification and 
institution of appropriate treatment is necessary to reduce the morbidity and 
mortality due to these organisms in hospitalised patients (12). 
 Different Acinetobacter species have differences in their antimicrobial 
susceptibility pattern, hence it is important to identify Acinetobacter isolates at 
species level (13). A.baumannii is the most common species isolated from clinical 
specimens and they developed 70% of resistance to third generation cephalosporins, 
aminoglycosides and quinolones. 87% of Acinetobacter isolates were Multidrug 
resistant (14). 
 In India, it has been reported that 66.7% isolates were ESBL producers, 
28.57% were AmpC producers, 16.67% were combined ESBL and AmpC producers 
and 47.6% were resistant to carbapenem drugs, in which 19% were MBL 
producers(11, 15, 16).  For ESBL and AmpC producers, carbapenem remain the drug of 
choice, whereas in carbapenem resistant strains we are left with Tigecycline and 
polymyxins which have started developing resistance to many GNBs (17). Hence the 
detection of carbapenem resistance is important in the treatment of patients and also 
preventing  the  spread  of  resistant  strains,  as  we  have  to  go  a  long  way  for  newer  
antibiotics. Carbapenem resistance in Acinetobacter may be due to oxacillinases, 
metallobeta lactamases, AmpC beta lactamases or due to porin deficiency (18). Since 
oxacillinases are chromosomally mediated, spread of OXA genes to other organisms 
is less frequent, when compared to MBLgenes, where the spread is plasmid 
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mediated and hence the propensity of dissemination is multifold. Also metallo beta 
lactamases are more potent (100-1000 fold) hydrolysers of carbapenems when 
compared to OXA type carbapenamases which contribute to the carbapenem 
resistance to a greater extent (16). 
 Since there are no CLSI guidelines for the detection of 
Metallobetalactamases, different studies used different methods. Despite PCR being 
highly accurate and reliable, its accessibility is limited only to reference laboratories. 
Various non-molecular methods have been studied, all by using the enzyme’s zinc 
dependence activity. Chelating agents, such as 2-mercaptopropionic acid, EDTA and 
other thiol compounds are used to inhibit its activity (19). 
         The present study was therefore taken to identify the nonfermenters from 
various clinical specimens and to determine their antimicrobial susceptibility pattern 
and to detect the production of Extended Spectrum Betalactamases in nonfermenters 
(ESBL) and also to detect the carbapenem resistance by different phenotypic 
methods  and  molecular  detection  of  resistant  genes  (blaVIM  and  IMP  and  OXA  -  
51) among Acinetobacter species., by PCR in the same isolates. This may provide 
the necessary information to formulate a hospital antibiotic policy and also to 
prevent the spread of multidrug resistance strains in the community. 
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AIMS AND OBJECTIVES 
1. To isolate, speciate and determine the antimicrobial susceptibility pattern 
of the Nonfermenting Gram negative bacilli. 
2.  To detect Extended Spectrum Betalactamases (ESBL) among the isolated 
nonfermenters 
3.  To detect Carbapenem resistance producing Acinetobacter spp., among 
the isolates   
4.  To confirm Oxacillanase (OXA) and Metallo Beta Lactamase ( MBL) 
production by phenotypic  & genotypic methods among the Acinetobacter 
spp., 
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REVIEW OF LITERATURE 
                    Nonfermenting Gram Negative Bacilli are a taxonomically diverse 
group of organisms growing significantly under aerobic conditions. They share 
common phenotypic feature of failing to acidify the butt of Triple sugar iron agar 
(TSI) or Kligler iron agar (KIA) agar or oxidative-fermentative (OF) media (20). 
 Aerobic nonfermenters are cosmopolitan in distribution inhabiting soil, 
water, plants and animals. Their medical importance is principally from their being 
opportunistic pathogens and clinical diseases they cause are nosocomial in origin.     
        Large group of these nonfermenters had undergone confusing taxonomic 
changes for many years. New definitions of species and genera using modern 
genotyping analysis, with reliable identification methods resulted in a better 
knowledge of these bacteria and significantly increased awareness of their 
pathogenic role in hospitals and in cases of community acquired infections (1,7). 
 The major genera of nonfermenting Gram negative bacilli have been 
classified into atleast 15 families (Alcaligenaceae, Alteromonadaceae, Brucellaceae, 
Burkholderiaceae, Caulobacteraceae, Comamonadaceae, Flavobacteriaceae, 
Methylobacteriaceae, Moraxellaceae, Oceanospirillaceae, Pseudomonadaceae, 
Rhizobiaceae, Sphingobacteriaceae, Sphingomonadaceae and Xanthomonadaceae). 
In addition to a number of clinically important nonfermenters which have uncertain 
taxonomic positions (1).   
 Medically important nonfermenters can be grouped on the basis of 
presence or absence of motility and the type of flagella present in strains that are 
motile: (1) 
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MOTILE WITH POLAR FLAGELLA 
FamilyPseudomonadaceae(rRNA groupI) 
Genus Pseudomonas 
Family Burkholderiaceae (rRNA group 
II) 
Genus Burkholderia 
Genus Cupriavidus 
Genus Lautropia 
Genus Pandoraea 
Genus Ralstonia 
Family Comamonadaceae 
 (rRNA group III) 
Genus Comamonas 
Genus Acidovorax 
Genus Delftia 
Family Caulobacteraceae (rRNA  
Group IV) 
Genus Brevundimonas 
Family Xanthomonadaceae  
(rRNA GroupV) 
Genus Stenotrophomonas 
Family Sphingomonadaceae  
Genus Sphingomonas 
 Family Oceanospirillaceae 
 Genus Balneatrix  
Family Alteromonadaceae  
Genus Alishewanella  
Genus Shewanella  
Family Oxalobacteraceae 
 Genus Herbaspirillum  
Genus Massilia 
 Family Methylobacteriaceae  
Genus Methylobacterium 
 Genus Roseomonas  
Organisms Whose Taxonomlc 
 Position Is Uncertain 
 CDC Groups Ic, O-l, O-2, O-3, Vb-3 
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    MOTILE WITH  PERITRICHOUS                                                          
                      FLAGELLA 
NONMOTILE,OXIDASE
NEGATIVE 
Family Alcaligenaceae 
Genus Achromobacter 
Genus Alcaligenes  
Genus Bordetella (B. avium, B. hinzii,  
 B. bronchiseptica, B. trematumatum)  
Genus Kerstersia  
Genus Oligella (O. ureolytica)  
Family Rhizobiaceae  
Genus Rhizobium  
Family Brucellaceae  
Genus Ochrobactrum  
Family Halomonadaceae  
Genus Halomonas 
Family Moraxellaceae 
Genus Acinetobacter 
Family Alcaligenaceae 
Genus Bordetella 
 (B.pertussis, B.parapertussis,  
 B. trematum) 
Organisms WhoseTaxonomlc Position 
Is Uncertain 
CDC group NO-1 
CDC group EO-5 
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NONMOTILE, OXIDASE POSITIVE 
Family Flavobacteriaceae 
Genus Flavobacterium 
Genus Bergeyella 
Genus Chryseobacterium 
Genus Empedobacter 
Genus Myroides 
Genus Weeksella 
Family Sphingobacteriaceae 
Genus Sphingobacterium 
Genus Pedobacter 
Family Moraxellaceae 
Genus Moraxella 
Genus Psychrobacter 
Family Neisseriaceae 
Genus Neisseria 
Family Alcaligenaceae 
Genus Oligella (O. urethralis) 
Family Rhodobacteraceae 
Genus Paracoccus (EO-2) 
OrganismsWhose Taxonomic Position 
Is Uncertain 
CDC groups EO-3, EO-4, EF-4b 
CDC groups lIc, IIe, Ilg, IIh. IIi, 
Gilardi rod group 1 
 
 Among these the most commonly isolated organisms in clinical 
specimens in descending order of importance are: 
                   1. Pseudomonas aeruginosa 
                   2. Acinetobacter baumannii 
                   3. Stenotrophomonas maltophilia 
                  4. Burkholderia cepacia 
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With species of Flavobactericeae family an Alcaligenes groups recently been 
recognized as potential pathogens (1). 
RISK FACTORS FOR THE DISEASES CAUSED BY NONFERMENTING 
GRAM NEGATIVE BACILLI (6, 7) 
1. Immunosuppression – Diabetes mellitus, steroids / antibiotic treatment, 
malignancy and transplantation. 
2. Trauma – gunshot, knife wounds, punctures, burns and surgical wounds  
3.  Foreign body implantation – catheters (urinary / blood stream), Prosthetic   
devices – corneal implants, contact lenses, joints, valves. 
4.  Infused fluids – dialysate, saline irrigations. 
5.  Prolonged hospitalization in Intensive Care Units. 
PSEUDOMONAS AERUGINOSA: 
 Ps.aeruginosa is  the  most  common  organism  isolated  among  the  
nonfermenters from  clinical specimens, more often than other Pseudomonas species 
especially in the teaching hospitals with more than 500 beds(6). They are ubiquitous 
organisms distributed widely in nature.  
 Nosocomial infections are infections causing serious threat to the 
community and reported in 5-10 percent of hospital admissions throughout the 
world. In India, the nosocomial infection rate is alarmingly rising and estimated to 
be about 30-35 percent of all the hospital admissions (21). 
11 
 Pseudomonas aeruginosa has become one of the most dreadful causes of 
nosocomial infections especially in the lung, urinary tract  and blood. As a result  of 
its considerable potential to become resistant to many antibiotics multidrug resistant 
strains are encountered as clinical isolates, leaving physicians with a decreasing 
armamentarium of effective drugs for treatment. 
TAXONOMY: 
 The genus Pseudomonas and some closely related genera, many of which 
were formerly placed in the genus Pseudomonas, make up a group often referred to 
as the pseudomonads. The Pseudomonads are classified into 5 ribosomal RNA 
homology groups by Palleroni (22) based on rRNA-DNA homology studies. On the 
other hand, Gilardi classified Pseudomonads into 7 major groups based on the 
phenotypic characters: fluorescent, stutzeri, alcaligenes, pseudomallei, acidovorans, 
facilis - delafieldi and diminuta (1). 
 Among the Pseudomonads, Pseudomonas aeruginosa is the well 
characterised and most frequently recovered Pseudomonad from the clinical 
specimens. P.aeruginosa infection is especially prevalent among the patients with 
burns, wounds, acute leukaemia, cystic fibrosis, organ transplants and intravenous 
drug addiction (23). 
HISTORY: 
 Before the advent of modern medical microbiology, there was evidence 
that P.aeruginosa was  a  cause  of  serious  wound  and  surgical  infections,  as  
elaborated by Doggett .In 1850, it was by Sedillot that there were sometimes blue 
green discharge on surgical dressings were associated with the infection. In 1862, 
Lucke first noted rod-shaped organism within the blue green pus. In 1882, Gessard 
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isolated the organism and originally designated them as bacillus pyocyaneus, and 
other early microbiologists also isolated the organism from infected sites. Osler in 
1925 thought that the organism to be more of a secondary opportunistic invader of 
damaged tissues as opposed to a primary cause of infection in healthy tissues (24). 
HABITAT: 
 P.aeruginosa is an opportunistic patthogen capable of causing infection in 
immunocompromised patients. In clinical medicine, P. aeruginosa has been 
primarily encountered as a nosocomial pathogen, which reflects its great propensity 
to grow in a variety of environment with minimal nutritional components (25). It is 
usually found in water, soil and plants and is associated with colonisation of healthy 
humans and animals. Up to 7% of healthy humans are colonised with P. aeruginosa  
in  nasal mucosa, throat and on the skin and a high rate of 24% carriage rates in stool 
are reported (26). The organism can tolerate temperatures to as high as 45ƕC to 50ƕC 
and  can  grow  in  distilled  water  using  dissolved  CO2 and residual iron, sulfur, 
phosphorus, and divalent cations such as carbon which can enhance the growth of 
P.aeruginosa even in antiseptic solutions and other liquids. 
 Within the health care setting, P.aeruginosa colonizes moist surfaces of 
patients on the ear, axilla and the perineum and is also found in moist inanimate 
environments including water in sinks, toilets and showers including antiseptic 
solutions which are used in the wards (27). Hospital equipments such as respiratory 
ventilators, cleansing solutions, mops are also the sources of P.aeruginosa infection. 
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MORPHOLOGY: 
 Pseudomonads are gram-negative straight or slightly curved rods arranged 
singly, in small bundles or short chains, non-sporing, non-acid-fast, strict aerobes, 
motile by polar flagella 
 CULTURAL CHARACTERISTICS: 
 P.aeruginosa grows readily on ordinary media and can utilize wide range 
of substrates as carbon and nitrogen sources and is identified by colonial 
appearances and characteristic grape–like smell of aminoacetophenone (24). 
P.aeruginosa strains exhibit a moth-eaten type of colonial lysis with metallic sheen 
known as iridescence. 
 Special media such as Pseudomonas isolation agar, Pseudomonas 
enrichment broth and Stewart’s arginine glucose (AG) medium.  And automated 
systems API 20NE test strips RapID NF Plus system are commercially available (28). 
PRODUCTION OF PIGMENTS: (28) 
1. Pyocyanin  -Demonstration  of  the  presence  of  blue  phenazine  pigment  is  
absolute confirmation of P.aerugonosa and is the major diagnostic test. 
2. Pyoverdin-The yellow/green pigment produced by most strains, giving the 
characteristics blue-green appearance of infected pus or cultures. 
3. Pyocyanin, pyoverdin pyorubin easily identified on nutrient or sensitivity 
test agars and pyomelanin require growth medium containing 1%tyrosine. 
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IDENTIFICATION: (1) 
 P.aeruginosa produces large flat colonies with spreading and serrated 
edges with metallic sheen. Various diffusible pigments are produced like pyoverdin 
and  pyocyanin..  On  blood  agar  it  is  beta  hemolytic.  It  produces  non-lactose  
fermenting colonies on MacConkey agar. They are motile. It is oxidase positive, 
catalase positive, indole negative, citrate and urease variable. It oxidizes glucose in 
OF media, reduces nitrates to nitrites, arginine is decarboxylated, acetamide 
positive, ONPG negative, sensitive to Polymixin B and grows at 42oC, differentiates 
it from Pseudomonas fluorescens and Pseudomonas putida. 
Minimum requirement for definitive identification of P. aeruginosa are: 
1. Gram negative rod 
2. Oxidase positive 
3. Typical smell (fruity grape-like odor or corn tortilla) 
4. Recognizable colony morphology 
a. On blood or chocolate agar appears as large colonies with metallic 
sheen, mucoid, rough, or pigmented (pyocyanin) and often ß-
hemolytic 
b. On MacConkey, appear as lactose-negative with green pigmentation, 
or metallic sheen 
VIRULENCE FACTORS OF PSEUDOMONAS AERUGINOSA: 
 The virulence is multifactorial including loss of host defence mechanisms 
like immunosuppression, loss of mucosal barrier, cellular factors, toxins elaborated 
by Ps.aeruginosa like endotoxins, exotoxin A, enzymes like elastases, alkaline 
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protease and hemolysins are responsible for many of the systemic manifestations of 
Pseudomonas disease (1, 6). In addition, the colonies of the organism form biofilms 
within which they are protected from host defenses and antimicrobial agents and 
communicate with each other through complex system of cell to cell signaling called 
Quorum sensing (28,6). The production of alginate and epithelial cell tropism in cystic 
fibrosis is associated with poor prognosis and high mortality (29) 
VIRULENCE FACTORS: (1) 
1. Alginate – Capsular polysaccharide allows the infecting bacteria to adhere 
to lung epithelial cell surfaces and form biofilms and protect the bacteria 
from antibiotics and host immune system. 
2. Pili –Surface appendages that allows adherence of the organism to GM-1 
ganglioside receptoron host epithelial surfaces. 
3. Neuraminidase-facilitating binding of pili by removing sialic acid 
residues from GM-1 ganglioside receptors 
4. Lipopolysaccharide-produces endotoxin, sepsis syndrome: fever, shock, 
oliguria, DIC, leucopenia and metabolic abnormalities 
5. Exotoxin A – causes tissue destruction by inhibiting protein synthesis, 
interrupts cell activity and macrophage response. 
6.  Enterotoxin – interrupts normal GI activity leading to diarrhoea. 
7.  Exoenzyme S –Inhibit protein synthesis. 
8. PhospholipaseC-Destroys cytoplasmic membrane and pulmonary 
surfactant, inactivates opsonins 
9.  Elastase – Cleaves immunoglobulins and compliment components, 
disrupts neutrophil activity 
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10. Leukocidin - Inhibits neutrophil and lymphocyte function 
11. Pyocyanins – Suppress other bacteria and disrupt respiratory ciliary 
activity, causes oxidative damage to the tissues. 
PATHOGENICITY: 
 P.aeruginosa is a highly pathogenic in humans because of multitude, 
diversity  and  complexity  of  its  virulence  factors.  All  major  classes  of  bacterial  
virulence systems are virtually found in this organism including exotoxins, 
endotoxins, leukocidin, type III secreted toxins, fimbriae, flagella, neuraminidase, 
elastase, proteases,  exoenzymes, phospolipases, iron binding proteins, exo-
polysaccharides (alginate) ,bacteriocins,  biofilm  formation  and pigment production 
such as pyocyanin(1). 
 The primary factor determining the pathogenic potential of P.aeruginosa 
is the immunological status of the human host. One important predisposing factor 
for community acquired and nosocomial P.aeruginosa infection is neutropenia (30). 
Disruption in anatomic barrier functions of skin and mucosal surfaces causes 
invasive infection. 
 Other infections caused by P. aeruginosa are osteochondritis, chronic 
suppurativeotitis media, external ear infections, meningitis followed by trauma and 
surgery, endochondritis and peritonitis (20, 31). 
 Patients with significant burns wound are at high risk for P.aeruginosa(32). 
Burn wounds, other types of wounds such as chronic non-healing ulcer, diabetic 
ulcer, ulcers due to malignancies, use of intravenous or urinay catheters, use of 
endotracheal tubes are the predisposing factors to acquire infection with 
P.aeruginosa. The healthy eye is highly resistant to P.aeruginosa infection, when 
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the physical integrity of corneal epithelium is lost it becomes a pathogen (33, 34).The 
organism can also cause dreadful infections of the eye. Pseudomonas keratitis and 
endophthalmitis are approached as medical emergency that can be fatal and threaten 
permanent loss of vision (33). Loss of mucosal barrier is also an important factor in  
invasive disease. Host factors that have been implicated in high level resistance to 
P.aeruginosa infection include complement proteins (35, 36) lung surfactants (37) and 
similar members of collectin family, a variety of cytokines and chemokines (36). 
 The production of mucoid morphotype is due to the production of large 
amounts of polysaccharide (alginate) (38), which is ultimately responsible for the 
poor prognosis and high mortality rates among the patients with cystic fibrosis (39). 
QUORUM SENSING - VIRULENCE FACTOR PRODUCTION & BIOFILM 
FORMATION: 
 Recently, small regulatory RNAs have been recognized whose expression 
is controlled by a repressor protein and these regulator RNAs control production of 
factors are known as quorum sensors that signal the organism how to respond to its 
environment. 
 Three important interrelated quorum sensing systems are known and 
designated as las, rhl and pseudomonas quinolone system. The molecular 
mediators of the quorum sensing are known as autoinducers (AI) .They have a role 
in regulation of gene transcription and virulence factor production which has been 
linked with PA01 chromosome in P.aeruginosa (40). 
 
 
18 
ANTIMICROBIAL SUSCEPTIBILITY: 
 They are sensitive to semisynthetic penicillins like Piperacillin, 
Ticaricillin, third generation cephalosporins (ceftazidime), carbapenams (imipenam 
and meropenam), monobactams, aminoglycosides and fluroquinolones (7,41). 
 It is intrinsically resistant to ampicillin, amoxycillin and amoxicillin-
clavulanic acid due to an inducible chromosomal AmpC beta lactamases. Multiple 
resistance in these organisms is frequent, leading to the development of multidrug 
and pandrug resistant P.aeruginosa strains caused by mutations & or production of 
betalactamases ranging from extended spectrum of betalactamases to 
metallobetalactamases (42, 20) 
MULTIDRUG RESISTANCE IN PSEUDOMONAS: 
 P. aeruginosa can develop resistance to antibiotics either through the 
acquisition of resistance genes on extra chromosomal mobile genetic elements (i.e., 
plasmids) or through the mutational mechanisms that alter the expression and 
function of chromosomally mediated mechanisms. Although the availability of 
certain agents like Doripenem and fourth generation cephalosporin, Cefipime 
provided the medical community with a certain degree of security, the situation has 
changed because of the selection strains of P. aeruginosa .Various definitions 
defining multi-drug resistant (MDR), extensively drug resistant (XDR) and pandrug-
resistant bacteria (PDR) including P. aeruginosa have been recently reported (43) 
PSEUDOMONAS STUTZERI: 
 The organisms in this group are all soil denitrifiers and can grow 
anaerobically in nitrate containing media, with production of nitrogen gas. Motile by 
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polar monotrichous flagella, grow with NH4 as  the  sole  source  of  nitrogen  and  
acetate as sole source of carbon for energy. 
 P.stutzeri (formerly CDC group Vb-1) is ubiquitous in soil and water and 
recovered from human s, manure, straw, sewage, stagnant water, baby formula, 
hospital equipment, eye cosmetics and various clinical specimens (24). 
 P.stutzeri has been associated with infections such as otitis media, 
conjunctivitis, pneumonia, septic arthritis, endocarditis, meningitis, infections of 
wounds and osteomyelitis (1). 
IDENTIFICATION: 
 Freshly isolated colonies are adherent and have a characteristic wrinkled 
appearance which may be lost on repeated subculture. They are catalase positive, 
oxidase positive , motile, oxidises glucose and maltose in OF media, reduces nitrate 
to nitrogen gas, doesnot decarboxylse lysine, arginine, acetamide negative and 
sensitive to polymyxin B (1) 
ANTIMICROBIAL SUSCEPTIBILITY 
 They are sensitive to semisynthetic penicillins like Piperacillin, 
Ticarcillin, third generation cephalosporins (ceftazidime), Carbapenems (Imipenem 
and Meropenem), Monobactams, aminoglycosides and Fluroquinolones. 
ACINETOBACTER SPECIES: 
 Acinetobacter are strict aerobic, gram negative coccobacillary rods, 
widely distributed in nature and hospital environments (20).  They are the second most 
commonly isolated nonfermenters in the clinical specimens next to Pseudomonas 
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aeruginosa  with a prevalence  rate of 10% of all Gram negative isolates(20,6). They 
are generally considered as non pathogic but cause serious infections in debilitated 
patients. The species most frequently isolated is Acinetobacter baumanii.  It is most 
often responsible for hospital acquired infections (20). They are the most common 
Gram-negative organisms to be isolated from the hands of medical personnel(6). 
 A study conducted by CDC reported that A.baumanii be the cause of 1% 
nosocomial blood stream infections (CDC).  A mortality of 17- 46% is associated 
with nosocomial bacteremia (44).   Analysis  of  data  from NNIS system showed that  
the proportion of ICU pneumonia episode ranges from 4% -7% (6). 
 These organisms have high rate of colonization of trachea. Respiratory 
tract is the most common site for A.baumanii infections in ICU with a mortality rate 
approaching 70% (45). Traumatic wounds, burns and postoperative surgical site 
infections are also common with multidrug resistant strains (3).   
TAXONOMY: 
HISTORY: 
 The Genus Acinetobacter has  colourful  taxonomic  history.  They  were  
identified in the first decade of the 20th century (9).  Acinetobacter was misidentified 
due to lack of differentiating features. 
        Genus Acinetobacter are a group of Gram negative bacteria belonging to 
Gammaproteobacteria (46). It was first described in 1908 as Diplococcus mucosus. 
The lack of distinctive characteristics was a driving force in the evolving 
nomenclature: Micrococcus (small), Mima (mimics), Achromobacter (colourless), 
Acinetobacter (motionless), and anitratus (nitrate not reducing). 
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 The first strain of Acinetobacter spp., were isolated by M.W. Beijerinck, a 
Dutch Microbiologist in 1911 from soil and were named as Micrococcus 
calcoaceticus (22). In the year 1930s and 1940s, De Bord proposed a new tribe, 
Mimaeae, to encompass these organisms. Later Brisou and Prevot in 1954 proposed 
the genus Acinetobacter to include colourless, nonmotile, saprophytic gram-negative 
bacilli regardless of the oxidase activity. 
 In the year 1971, the Subcommittee on the Taxonomy of Moraxella and 
Allied Bacteria proposed that the genus Acinetobacter should include only the 
oxidase negative strains (22). In the year 1984, Bergey’s Manual of Systematic 
Bacteriology classified Acinetobacter in the family Neisseriaceae, but more recently 
the molecular taxonomic studies have resulted in the reclassification of this 
organism in the new family Moraxellaceae in 1991(46). This family also includes 
Moraxella, Psychrobacter and related organisms. The genus Acinetobacter belongs 
to:-  
Phylum  - Proteobacteria 
Class  - Gammaproteobacteria 
Order  - Pseudomonadales 
Family  - Moraxellaceae 
Genus  - Acinetobacter 
CLASSIFICATION: 
 The genus characteristic of Acinetobacter was made clear by 1971. They 
are Gram negative rods or coccobacilli, catalase positive, oxidase negative, non- 
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motile, non-sporing and may be capsulated. Phenotypic identification is possible 
using a scheme proposed by Bouvet and Grimont (47). 
 The first species identified was A.calcoaceticus. Initially the scientists had 
distinguished the species based on the ability to produce acid from glucose or not, 
A.calcoaceticus was distinguished into two variants, A.calcoaceticus var.anitratus 
which produces acid from glucose and A.calcoaceticaus var.lwoffii which do not 
produce acid (9). 
 Other methods of species identification includes bacteriocin typing, phage 
typing, characterization of outer membrane proteins, serotyping, phenotyping, 
ribotyping, transfer ribonucleic acid (tRNA), genomic fingerprinting and DNA 
homology studies (22). 
 The Epidemiological identification was done using pulsed field gel 
electrophoresis, amplified fragment length polymorphism(AFLP), randomly 
amplified polymorphic DNApolymerase chain reaction(RAPD-PCR), MLST, 
electrospray ionization mass spectrometry (PCR/ESI-MS) or ribotyping(48), 
Fluorescent Lactose Denitrification (FLN) was used to identify  different species of 
bacteria in this genus by the amount of acid produced due to metabolism of 
glucose(49). 
 In 1986, based on DNA-DNA hybridization studies Bouvet & Grimont 
identified 12 genomic species. In 1989 it is increased to 17, now 33 different 
genomic species have been identified, of which 17 have been named and others will 
carry the genomic species number (50). 
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Acinetobacter Nomenclature: 
 Acinetobacter calcoaceticus (genomic species 1), A.baumannii (genomic 
species 2), A.haemolyticus (genomic species 4), A.junii (genomic species 5), 
A.johnsonii (genomic species 7), A.lwoffii (genomic species 8/9), A.radioresistens 
(genomic species 12), A.baylyi, A.bouvetii, A.gerneri, A.grimontii, A.parvus, 
A.schindleri, A.tandoii, A.tjernbergiae, A.towneri, A.ursingii, A.venetianus and 
Acinetobacter species unnamed Genomospecies 1,2,3 and 13 of Tjernberg and 
Ursing may be difficult to distinguish in the clinical laboratory and have been 
referred to as Acinetobacter calcoaceticus-baumannii complex (22). 
MORPHOLOGY: 
 Members of the genus Acinetobacter are Gram negative rods or 
coccobacilli. During the exponential phase they appear bacillary to coccobacillary 
but become more coccoid or diplococcal in the stationary phase and in non selective 
media (22). Individual cells are 1 to 1.5 by 1.5 to 2.5ȝm in size.  
CULTURAL CHARACTERISTICS: 
 Members of the genus Acinetobacter are strict  aerobic, catalase positive, 
oxidase negative,  Gram negative rods growing at a wide range of temperatures  
(often upto 42°C and pH, optimally at 37°C) .They may be capsulated in older 
cultures, non-motile occasionally an odd twitching motility can be demonstrated and 
non- sporing (22). They do not reduce nitrates to nitrites, this distinguishes these 
organisms from Enterobacteriaceae (9). They are not fastidious and most strains 
grow in defined media containing single carbon and energy source which accounts 
for its prevalence in nature (48). 
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 The colonies are 1-2mm in diameter which is smaller, dome shaped, 
smooth, slightly mucoid and opaque with grayish white or pale yellow pigmentation. 
Acinetobacter are nonlactose fermenters but it may produce a pinkish hue on 
MacConkey agar (22). Hemolytic property on Blood agar is variable. 
 Some special media like Herellea Agar, Leeds Acinetobacter Medium and 
Liquid Enrichment medium have been used for the isolation of Acinetobacter 
species from various clinical specimens and from environmental samples (50). 
 BIOCHEMICAL CHARACTERISTICS: 
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A.calcoaceticus 1 + - - + + + 
A.baumanii 2 + + - + + + 
A.haemolyticus 4 + - + V + - 
A.lwoffii 8/9 + - - - - - 
A.junii 5 + - - - + - 
A.johnsonii 7 + - - - V V 
 
 The Genus Acinetobacter does not form Indole,  does not acidify the butt  
of TSI, citrate is not utilized, urease is not produced and nitrate is not reduced to 
nitrites (1). Main differentiation between the species is based on the saccharolytic 
property. It acidifies most OF carbohydrates; in particular definitive identification is 
made by demonstrating the rapid production of acid from 1% or 10% lactose. 
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AUTOMATED METHODS FOR IDENTIFICATION: 
 Vitek  2  and  Phoenix  are  the  two  methods  which  are  available  for  
detection of Acinetobacter from specimens, but their detection rate to identify the 
organism at species level is poor. Hence it is not used routinely. 
 EPIDEMIOLOGY: 
 Acinetobacter species are ubiquitous in the environment(22). Acinetobacter 
species may be isolated from a common source such as computer key boards, Bp 
cuffs, parenteral nutrition or mechanical ventilator or from the dialysis machine (48). 
 They are normally isolated from the moist areas like axilla, groin and toe 
webs. They are commensals in the respiratory tract (7%) and exhibit 25% of 
cutaneous colonization in healthy adults (9). A.lwoffii (58- 61%) is the most common 
skin colonizer followed by A.johnsonii (20%), genomospecies 15 (12%), A.junii 
(10%), A.radioresistens (8%), genomospecies 3 (5%) and A.baumannii (0.5-3%). 
Generally it colonizes the human skin 44% in non-hospitalized and 75% in 
hospitalized patients (48). A.baumannii colonization is very low in normal individuals 
but it has higher end during hospitalization. 
BURDEN OF DISEASE: 
WORLDWIDE: 
 The multidrug resistant Acinetobacter spp., especially Acinetobacter 
calcoaceticus baumannii complex isolates showing a rising trend all over the world. 
The first carbapenamase enzyme resistance strain was found in Scotland in 1985(51). 
Till 2002 carbapenem resistance was not a major health problem in Europe.  From 
2003 the isolation of resistant strains has been increased.  
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 Carbapenem resistance seems to be highest in the countries of Turkey, 
Greece,  Italy,  and  England  and  the  rates  appear  to  be  the  least  in  countries  of  
Germany and Netherlands. Pneumonia due to Acinetobacter in critically ill patients 
is more in Asia (4-44%) and European (0-35%) hospitals than in US hospitals       
(6-11%). The Acinetobacter isolates from Asian and European countries were 
resistant to aminoglycosides and Piperazillin Tazobactum in higher proportion when 
compared to The United States. This data suggests that the growing threat of 
Acinetobacter infection in critically ill patients especially in Asia and Europe (52). 
INDIA: 
 In India, it has been reported that 66.7% isolates were ESBL producers, 
28.57% were AmpC producers, 16.67% were combined ESBL and AmpC producers 
and 47.6% were resistant to carbapenem drugs, in which 19% were MBL 
producers(11,15,16). 
 Carbepenem resistance is reported from various parts of India. A study 
conducted by Sinha et al. in 2011 in North India showed 87% of isolates were MDR 
and 20% were resistant to Meropenem.(9).  Similarly a study conducted in the same 
year showed 14.8% of A.baumannii isolates were Meropenem resistant (53). 
 An incidence of 14.2% Acinetobacter strains were resistant to 
carbapenem was documented in a study from Christian Medical College, Vellore.(54) 
Similarly a study from All India Institute of Medical Sciences, New Delhi in 2005 
has  given  a  prevalence  of  34.7%  resistance  to  meropenem,   St.  John’s  Medical  
College, Bangalore showed resistance rate of 14% and from Chandigarh in 2003 
resistance rate of 20% have been documented.(55,18) 
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PATHOGENESIS: 
VIRULENCE FACTORS (22) 
x Lipopolysaccharide – Because of lipopolysaccharide, Acinetobacter 
O antigen display a marked hydrophobicity with the ability to grow 
on hydrophobic substrates. 
x Capsule – The presence of polysaccharide capsule protects it against 
phagocytosis. 
x Fimbriae – Fimbriae facilitate the adhesion to the human epithelial 
cells. 
x Protein S layers and Slime also potentially enhance the virulence of 
the organism. 
x Certain strains of Acinetobacter have been shown to produce 
siderophores and iron-repressible outer membrane receptor proteins. 
x Enzymes – Enzymes butyrate esterase, caprylate esterase and leucine 
arylamidase potentially involved in damaging tissue lipids. 
x Bacteriocin production may enhance the survival of 
Acinetobacter.(55) 
x Biofilm – Biofilm formation is a well known pathogenic mechanism 
in device associated infections. The excess polysaccharide formation 
in A.baumannii leads to difficulty in antibiotic penetration and the 
differences in cell physiology in biofilm increases the drug 
resistance(56). 
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CLINICAL MANIFESTATIONS: 
 The major drawback in the identification of Acinetobacter infection is the 
interpretation in the significance of isolates from the clinical samples (9). 
RESPIRATORY TRACT: 
 This is the most common site of infection due to pharyngeal colonization. 
Community acquired bronchiolitis and tracheobronchitis have been reported in 
healthy children (9). Similarly 10% of community acquired pneumonia in adults is 
due to Acinetobacter species and it accounts for 20% of Gram negative pneumonia. 
The major impact is the ventilator associated pneumonia in ICU patients due to 
nosocomial spread. It is also associated with high mortality rate of 40% to 60% (48).  
BACTEREMIA: 
 The bacteremia due to Acinetobacter will occur late during 
hospitalization. It is mainly followed by respiratory tract infections and through the 
indwelling catheters. A.baumannii was the tenth most common cause for 
monomicrobial blood stream infections and the mortality rate was 17% to 46%, 
followed by A.lwoffii, A. junii and A.parvus. (48) 
URINARY TRACT: 
 Acinetobacter though  colonizes  the  lower  urinary  tract,  it  is  rarely  
invasive. Indwelling bladder catheter or nephrolithiasis may cause cystitis and 
pyelonephritis due to Acinetobacter. (9) 
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SOFT TISSUE INFECTION: 
 The major pathogen in traumatic wounds, postoperative wounds and 
burns is Acinetobacter because of its ability to thrive in the devitalized tissues. 
MISCELLANEOUS INFECTIONS: 
 Acinetobacter spp may also be reported from various clinical syndromes 
like intracranial infections, soft tissue infections, conjunctivitis, endophthalmitis, 
endocarditis, arthritis, osteomyelitis, pancreatitis and liver abscess.(57) 
RISK FACTORS: 
 Acinetobacters are generally non pathogenic but it can cause infections in 
debilitated individuals. It is the second most common nonfermenter isolated from 
the human specimens next to P.aeruginosa. (20) 
 Risk factors for the community acquired infections include alcoholism, 
cigarette smoking, chronic lung disease and diabetes mellitus. For nosocomial 
infections the length of hospital stay is the most important cause followed by 
surgery, wounds, fecal colonization, indwelling catheters, admission to ICU or burns 
unit, parenteral nutrition, mechanical ventilation and breaches in infection control 
protocols. 
ANTIMICROBIAL SUSCEPTIBILITY PATTERN: 
 Different species of Acinetobacter exhibit differences in antimicrobial 
susceptibility pattern (13). Hence species identification and its specific susceptibility 
pattern is very essential. Initially Acinetobacter infections were treated with beta 
lactam antibiotics like third generation cephalosporins, extended spectrum 
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penicillins, penicillins-beta lactam inhibitor combinations and fluoroquinolones.(58) 
Nowadays due to the development of various resistance mechanisms, the antibiotic 
treatment regimen for Acinetobacter infection has been very much narrowed. 
MECHANISM OF RESISTANCE: 
Resistance to Carbapenems: 
 Till the emergence of Imipenem resistant Acinetobacter strains 
Carbapenem remained the only drug to treat severe Acinetobacter infections. Due to 
the emergence of Carbapenem resistant strains, Polymyxins and Tigecycline came to 
be in use, which also developed resistance in recent years.(53,59,60)   
 The carbapenem resistance is also mediated by AmpC betalactamases 
when present along with decreased membrane permeability or due to alterations in 
penicillin binding proteins.(123,124) The extent of antimicrobial resistance in 
Acinetobacter spp. can be explained with varied definitions. 
x Multi Drug Resistant (MDR) – The isolate resistant to at least three 
classes of antimicrobial agents including all penicillins, 
cephalosporins, fluoroquinolones and aminoglycosides. 
x Extensive Drug Resistant (XDR) - The isolate will be resistant to 
carbapenems in addition to the above mentioned drugs. 
x Pan Drug Resistant (PDR) – The isolate will be resistant to all the 
available drugs, including polymyxins and tigecycline. 
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 The mechanism of resistance in Acinetobacter involves the following 
three broad categories (10): 
1. Antimicrobial inactivating enzymes. 
2. Reduced access to bacterial targets 
3. Point mutations that change targets or cellular functions. 
Treatment of MDR, XDR and PDR Acinetobacter species: 
 Carbapenem remains the drug of choice for the treatment of MDR 
Acinetobacter spp., The treatment of XDR Acinetobacter spp,.infections include 
Polymyxins and Tigecycline as the last resort.(61) . 
Combination Therapy: 
 The combination therapy including rifampicin, sulbactam, 
aminoglycosides, carbapenems and colistin can be tried for treating XDR and PDR 
Acinetobacter spp.,(49,60,62). 
CONTROL MEASURES: 
 Stringent measures should be taken to control and prevent the spread of 
MDR Acinetobacter infections (63). 
Infection control practices (63) 
1.  Standard precautions, environmental cleaning and disinfection. 
2.  Source control effective during the outbreak. 
3.  Contact barrier precaution to health care personnel. 
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4.  Cohorting the patients. 
5.  Cohorting of healthcare personnel. 
6.  Judicious use of antimicrobials to prevent drug resistance by 
antimicrobial stewardship. 
8.  Passive and active surveillance to identify colonized or infected 
patients, so that interventions can be implemented. 
STENOTROPHOMONAS MALTOPHILIA: 
 Originally classified as Pseudomonas maltophilia, it is an obligate aerobe 
and an ubiquitous organism (1). Ocassionally causes opportunistic infections and  is 
an emerging opportunistic pathogen.(64) It is the third most commonly encountered 
nonfermenter in clinical laboratory next to Pseudomonas and Acinetobacter(1,7). 
 It is an important nosocomial pathogen associated with substantial 
morbidity and Mortality rate of 43% especially in immunosuppressed patients, 
patient in intensive care unit, and pulmonary source of the isolate. The most 
common site for recovery of Stenotrophomonas maltophilia is  the respiratory tract.  
It  is  one  among the  most  common causes  of  wound infections  due  to  trauma.  It  is  
frequently isolated from patients with ventilator support in ICU (20).   It  is  an  
important pathogen in cystic fibrosis patients (1). It produces proteolytic enzymes, 
deoxyribonucleases, ribonucleases, hemolysins, hyaluronidase and mucinase etc. 
which contribute to its severity in immunosuppressed patients (7). 
 The rate of infections caused by S.maltophilia is increased in recent years 
and are being isolated from wound infections, bacteremia, pneumonia, endocarditis, 
urinary tract infections, meningitis and peritonitis (20) 
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IDENTIFICATION: (1, 64)     
 S.maltophilia is  a  motile  rod,  with  polar  multitrichous  flagella  and  
distinguished from pseudomonads by virtue of being lysine and DNAse positive and 
oxidase negative. S.maltophilia is susceptible to colistin and polymyxin. This 
property is used to distinguish it from B.cepacia. Colonies formed are pale yellow / 
lavender green with good growth on Blood agar and MacConkey agar. It is oxidase 
negative, motile, catalase positive, indole negative, citrate variable, urease negative. 
It oxidizes glucose and maltose, decarboxylates lysine, ONPG positive, with 
variable nitrate reduction. 
 The following are the characteristics by which presumptive identification 
of can be made: 
x Good growth on blood and MacConkey agars 
x Donot produce cytochrome oxidase 
x Produce acid in OF maltose but may be negative in OF glucose 
x Lysine decarboxylase – positive  
x DNase – positive  
x Some strains have yellow pigment 
ANTIMICROBIAL SUSCEPTIBILITY: 
 The  antibiotic  susceptibility  pattern  can  be  a  clue  to  the  identification  of  
S.maltophilia. The most active agents are trimethoprim sulphamethoxazole, colistin 
and quinolones.  
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 Like other nonfermenters it is intrinsically resistant to many common 
antibiotics like aminoglycosides, carbapenams and many betalactam agents (1).  
BURKHOLDERIA CEPACIA:       
 It is a motile free living phytopathogen identified as both endemic and 
epidemic nosocomial pathogen (64).  Its  detection  rates  are  low,  in  the  range  of  1%-
16% of clinical samples (6).  It belongs to rRNA group Ie. Recent taxonomic 
advances demonstrated that B.cepacia is a cluster of atleast nine closely related 
genomic species now called B.cepacia complex and includes B.cepacia, 
B.multivorans,  B.cenocepacia, B.stablis,  B.vietnamiensis, B.dolosa, B.ambifaria, 
B.anthina and B.pyrocinia which can be differentiated on the basis of molecular and 
biochemical tests.(1) 
 These bacteria are most frequently associated with epidemic spread and 
with ‘Cepacia syndrome’ which is manifested by severe progressive respiratory 
failure and bacterimia. These strains are transmissible between patients and cross 
infection occur by person-to-person spread.  
VIRULENCE FACTORS: 
x Virulence markers such as cable(cbl) pilus encoded by cable pilin 
subunit gene(cblA) mediates adherence to mucus glycoproteins and 
enhances adherence to epithelial cells. 
x B.cepacia epidemic strain marker (BCESM) has association with 
B.cepacia strain types infecting multiple patients with CF 
x Virulence factors like proteases, lipases, exopolysaccharides and 
lipopolysaccharides (8,1). 
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PATHOGENESIS:            
 A few case reports have described serious infections, including severe 
pneumonia, Invasive otitis and sepsis in cystic fibrosis patients (7) Diabetes mellitus 
is a potential risk factor for development of infections.by B.cepacia (1). 
 B.cepacia is an important pathogen among patients with chronic 
granulomatous disease and cystic fibrosis. Like other nonfermenters, it can 
contaminate disinfectant solutions, intravenous solutions, nebulizer solutions, mouth 
wash and medical equipments. 
 The major importance of this organism lies in its role as opportunistic 
agent of pneumonia in cystic fibrosis patients seeded in sputum samples (65). 
 The spectrum of infections by these organisms includes wound infections, 
bacteremia, UTI, pneumonia, meningitis, peritonitis, and endocarditis (6). 
IDENTIFICATION: (1)          
 Colonies are smooth and glistening, forming non-lactose fermenting 
colonies on MacConkey agar and yellow pigmented colonies on blood agar. It is 
weakly oxidase positive, catalase positive, motile, oxidizes all sugars, 
decarboxylates lysine, ONPG negative, acetamide negative and resistant to 
Polymixin B. Nitrate reduction is variable. 
Selective media: 
x Pseudomonas cepacia medium (PCM)-containing crystal violet, 
polymyxin B and ticarcillin. 
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x OFPBL medium – containing polymyxin B, bacitracin and lactose 
x Burkholderia cepacia selective agar (BCSA) –containing lactose, 
sucrose, polymyxin B, gentamycin and vancomycin 
x BCSA and Mast B.cepacia medium – the most suitable for the growth 
of all B.cepacia complexes. 
x Commercial identification system – RapID NF Plus(Remel), API 
Rapid NFT(renamed API 20NE biomeriux), VitekGNI (biomerieux), 
and Uni-N/F Tek (Remel) 
ANTIMICROBIAL SUSCEPTIBILITY: 
 As with other nonfermenters, intrinsic antibiotic resistance to 
aminoglycosides, Polymyxin B typifies B.cepacia and greatly complicates 
treatment. Trimethoprim-sulfamethoxazole has historically been the drug of choice. 
Most active agents are, Minocycline, ceftazidime, meropenam, Rifampicin, 
ciprofloxacin and other quinolones (9,1,10). 
MULTIDRUG RESISTANCE IN NONFERMENTING GRAM NEGATIVE 
BACILLI: 
 Nonfermenting Gram Negative Bacilli pose a particular difficulty for 
healthcare community because they represent the problem of multidrug resistance to 
the maximum (53) .They are resistant to three or more drugs and important members 
of this group are P. aeruginosa, A. baumannii, S.maltophilia and B.cepacia (66). 
They use several mechanism of resistance including intrinsic and acquired 
resistance. Intrinsic resistance is due to relative impermeability of outer membrane 
proteins compared to that of other gram negative bacteria. Efflux system also 
contributes to intrinsic resistance. 
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 Acquired resisitance is by mutational changes and acquisition of 
exogenous genetic material. Lastly resistance may also develop during therapy 
turning as an initially susceptible into a resistant one.(29)  
 The increase in multidrug resistant strains suggests therapy with 
compounds like polymyxin B or colistin must be considered.(53) 
MECHANISMS OF ANTIMICROBIAL RESISTANCE AND BETA 
LACTAMASES 
 Bacteria can express more than one mechanism of antibiotic resistance 
leading to MDR or pandrug resistance. Molecular analysis of nonfermenter isolates 
from a nosocomial outbreak revealed convergence of several strategies for antibiotic 
resistance.(i).Over expression of Amp C chromosomal ȕ-lactamases conferring 
resistance to ȕ-lactams. (67) (ii) Mutational porin loss of OPr D porin, conferring 
resistance to Imipenem (iii) Upregulation  of  Mex  XY  efflux  system(68) exports 
Fluoroquinolones, Tetracyclines, Aminoglycosides and Antipseudomonal ȕ lactam 
agents.  
BETALACTAMASES – CLASSIFICATION: 
 ȕ –Lactamases are classes of enzymes that inactivate ȕ –lactam antibiotics 
by splitting the amide bond of the ȕ lactam ring mediated by either chromosomal 
genes or by transferrable genes located on plasmids and transposons. In addition, ȕ – 
lactamases genes bla frequently reside on the integrons, which often carry multiple 
resistant determinants. 
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The beta-lactamases are classified by two systems: Ambler’s classification – It is a 
molecular classification based on amino acid sequences. (69) 
 Bush-Jacoby Medeiros classification – It is a functional classification. (70) 
x Ambler’s Classification: 
Class A - Penicillinase (eg.TEM, SHV) 
Class B - Metallo betalactamase (eg.IMP, VIM) 
Class C - Cephalosporinase –AmpC (eg.CMY, NMC) 
Class D - Oxacillinase (eg.OXA 23, OXA 58) 
Class A, C and D require serine moieties for their function, similarly 
Class B require zinc for its action.  
x Bush-Jacoby Medeiros classification 
Group Enzyme Molecular class Inhibited by Clavulanic acid 
1 Cephalosporinase C No 
2a Penicillinase A Yes 
2b Broad spectrum A Yes 
2be Extended spectrum A Yes 
2br Inhibitor resistant A Diminished 
2c Carbenicillinase A Yes 
2d Cloxacillinase D or A Yes 
2e Cephalosporinase A Yes 
2f Carbapenemase A Yes 
3 Carbapenemase B No 
4 Penicillinase  No 
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 The beta-lactamases may be chromosomal or plasmid mediated. 
EXTENDED SPECTRUM OF BETALACTAMASES: (53, 71) 
 ESBL are a group of betalactamases which share the ability to hydrolyse 
third generation cephalosporins and are inhibited by clavulanic acid. They are 
plasmid coded Carbapenams are treatment of choice for serious infections due to 
ESBL producing organisms. ESBLs in nonfermenters are Ambler class A. These 
enzymes  are  SHVtype,  TEM type,  TEM 1 and  2,  CTX-M type,  OXA- type,  PER-  
type, VEB, BES – types and others. 
 Screening tests for ESBL producers are disk diffusion and dilution 
susceptibility testing methods. 
The phenotypic confirmatory tests for ESBL production are: (72) 
1. Cephalosporin / clavulanate combination disks. 
2. Broth microdilution tests  
3. E tests 
CARBAPENAMASES AND METALLOBETALACTAMASES (6,73,74) 
 Carbapenamases are betalactamases with versatile hydrolytic capacities. 
They have the ability to hydrolyze penicillins, cephalosporins, monobactams, and 
carbapenams. Bacteria producing these betalactamases may cause serious infections 
in which the carbapenamases activity renders many betalactams ineffective. They 
are members of molecular class A, B and D betalactamases. Class A and D have 
serine based hydrolytic mechanisms while class B are metallobetalactamases that 
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contain zinc in the active site. Class D carbapenamases consist of OXA type 
betalactamases frequently detected in Acinetobacter baumanii.  
 The metallobetalactamases belong to IMP, VIM, SPM, GIM and SIM 
families and have been detected primarily in Pseudomonas aeruginosa. 
Nonfermenters especially P.aeruginosa and A.baumanii have acquired 
metallobetalactamases through genetic elements (plasmids / transposons) and can be 
transmitted to other bacteria.  
 These enzymes confer resistance to all carbapenams (Imipenams, 
Meropenams, Ertapenams), all betalactams, aminoglycosides and quinolones. The 
dissemination is thought to be driven by regional consumption of ESBLs. 
 S.maltophilia is naturally resistant to imipenam and meropenam because 
of chromosomally mediated carbapenamase production (6,11) 
 The families and subgroups of carbapenamases known till now are IMP-
1&2, VIM-1&2, SPM-1, GIM-1, and SIM-1. IMP was first discovered in 
Ps.aeruginosa in Japan and this has spread to other gram negative bacteria and 
reports show their detection in A.baumanii, Serratia and Klebsiella. Currently IMP 
family member number upto 18 in the published literature. 
 The identification of MBL and other Carbapenemases is of prime 
importance in choosing the most appropriate antibiotic for the treatment of 
carbapenem resistant isolates in any health care set up. The severity of infection can 
be decreased by early and prompt detection and appropriate treatment before the 
bacteria change to a mucoid phenotype, which extremely difficult to eradicate if 
once established.  
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 Common antipseudomonal drugs are Carbenecillin, Ceftazidine, 
Piperacillin-Tazobactum & Cefoperazone – Sulbactum. The Carbapenems are one of 
the last resorts for the treatment of serious multi-drug resistant infection. 
Meropenem, Ertapenem and Imipenem/Cilastin are effective against most ESBL and 
AmpC producing organisms. Though these novel carbapenems are more effective 
against Multi Drug Resistant infections, resistance is still mediated through OprD 
deletions and spread of broad-spectrum Carbapenemases and MBLs. In various 
studies, intravenous Colistin with Rifampin and Imipenem was suggested for the 
treatment of Carbapenem resistant isolates without MBL production, whereas the 
combination of Colistin and Rifampicin with or without Tigecycline was suggested 
for treatment of MBL producing Carbapenem resistant isolates described 
byVikasmanchanda et al. (12), and Maragakis LL et al.,(75)  
 The medical community has now started  to use  drugs like Colistin and 
Polymyxin B which were once not used  due to their toxicity but are now being 
considered as ‘‘antimicrobials for the 21st century’’ (76). However some 
researchers reported emergence of Colistin resistant organisms in their study (77), 
which necessitates the discovery of newer molecules to treat the patients earlier and 
prevent the development and dissemination of resistance in the future. 
DETECTION OF CARBAPENAMASES: (6) 
1. Raise in MIC of carbapenams of  >8 ȝgm / ml. 
2.  Microbiological test with inhibitors: 
(i) Disc approximation test with EDTA  
(ii) Combined disc method: Imipenam with EDTA  
(iii)  E test strips with Imipenam and Imipenam EDTA combination 
(iv)  Modified Hodge test 
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 Of these tests, studies conducted showed that both combined disc test and 
E test were more sensitive and equally effective for MBL detection  
MOLECULAR METHODS: (6,78,79) 
 When the presence of a carbapenamase is suspectd, PCR is the fastest 
way to determine which family of betalactamase is present.  
Polymerase Chain Reaction (PCR): 
 Technique which amplifies a specific DNA target region,  to obtain a 
million or more copies which can  be easily visualized by using DNA staining 
techniques for  identification of resistance conferring genes. PCR is the gold 
standard procedure to determine the resistant genes, since the phenotypic methods 
have not yet been standardized for NFGNB. 
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MATERIALS   AND   METHODS 
Study design:  Cross sectional study 
Study period:  The study period was one year from July 2014 to June 2015. 
Place of Study: This study was conducted in the Department of Microbiology, 
Chengalpattu Medical College and Hospital, Chengalpattu. 
Sampling method: Random sampling 
Study Population: 
 Samples were collected from various patients who attended Chengalpattu 
medical college hospital and satisfied the inclusion criteria. Out of the samples 
collected, total of 110 isolates of Nonfermenters were isolated and speciation and 
antimicrobial susceptibilility testing was done according to Clinical Laboratories 
Standard Institute (CLSI) guidelines. Isolates included in this study were obtained 
from blood, sputum, endotracheal aspirate, bronchial wash, pleural fluid, ascitic 
fluid, peritoneal dialysis fluid, cerebrospinal fluid, urine and wound swabs. 
Inclusion Criteria: 
x Patients of all age groups coming to the outpatient department of 
Chengalpattu Medical College Hospital with various illnesses. 
x Hospitalised patients undergoing treatment in ICU medical, surgical 
and paediatric ward. 
x Patients affected with burn wounds, Patients with non-healing ulcer 
x Diabetic patients with ulcers 
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x Patients with provisional diagnosis of Septicaemia and Pneumonia  
x Patients with indwelling urinary catheter and on ventilators 
x Patients with long period of stay in the hospital  
x Patients with peritonitis 
EXCLUTION CRITERIA 
x Patients on prior antibiotic therapy 
x Isolates of repeated samples from the same patient were not included 
in the study. 
x Patient who do not  give consent 
Ethical consideration: 
 Approval was obtained from the Institutional ethical committee at 
Chengalpattu Medical College before the commencement of the study. Informed 
consent was obtained from all the patients participated in this study. All patients 
satisfying the inclusion criteria were included. Patients were interviewed by 
structured questionnaire. 
Statistical analysis: 
 Statistical analyses were carried out using Statistical Package for Social 
Sciences (SPSS).  
COLLECTION OF SPECIMENS 
 Collection of Blood sample: 
 Blood  samples  were  collected  by  strict  aseptic  technique.  The  skin  over  
the vene puncture site approximately 5cm diameter was cleaned thoroughly with   
45 
70 % ethanol followed by povidone iodine and allowed to dry at least for one minute 
before  collecting  the  sample.  5  ml  of  blood  was  collected  in  50  ml  of  Brain  Heart  
Infusion Broth (B.H.I) in adults. In the paediatric age group 1 to 5 ml of blood was 
collected in appropriate quantity of B.H.I. 
 Collection of Pus sample: 
 Sterile cotton wool swabs were used to collect the sample from infected 
sites. The swabs were transported in sterile test tubes to the laboratory. Two swabs 
were collected from patients and subjected to direct smear and culture.  
x Collection of Sputum sample: 
 The patients were asked to cough deeply before collecting the sputum to 
avoid mixing of saliva with the sputum. It was collected in the morning before any 
mouthwash  was  used  and  mouth  should  be  rinsed  with  saline  or  water  just  before  
expectoration. Clean, dry, sterile wide mouthed, screw capped and leak proof 
containers were used for sputum collection. 
 Collection of Urine sample: 
 Patients were instructed for proper collection of urine samples without 
any contamination. Male patients were asked to retract the prepuce and clean the 
urethral meatus with saline and to collect the early morning, mid stream urine. 
Female patients were asked to clean the genitals with soap and water and to dry the 
area with sterile gauze pad. The urine was collected with the labia held apart. The 
specimen was collected in a clean, wide mouthed, screw capped and leak proof 
container and transported to the laboratory without any delay. 
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 Collection of wound swab: 
 In cases of burn wounds and diabetic patients with ulcers, the wound site 
is cleaned with sterile saline and before application of any topical antibiotic 
preparation;  two  swabs  were  taken  with  sterile  cotton  swabs  from  the  edge  of  the  
wound with active infection. The swabs are moistened with sterile saline before 
collecting the specimen to avoid drying of the specimen before processing.  
x Collection of Endotracheal aspirate:       
 In patients with tracheostomies, who were unable to produce sputum, the 
endotracheal secretions were collected by aspirating the fluid by suctioning. The 
specimen was collected in a sterile container and transported immediately to the 
laboratory.                 
x Collection of  Bronchoalveolar Lavage (BAL): 
 Bronchoscopy assisted bronchial washings or aspirates were obtained by 
instilling a small amount of sterile physiological saline into the bronchial tree and by 
withdrawing  the  fluid.  The  specimen  was  collected  in  a  sterile  container  and  
transported immediately to the laboratory. 
 Collection of ascitic fluid: 
 The  skin  over  the  site  of  collection  was  sterilized  with  70% alcohol  and  
atleast 10 ml of fluid was aspirated with sterile syringe and needle and collected in a 
sterile tube or vial and transported to the laboratory.  
 The collected specimens were properly labeled with Name, Age, Sex, I.P/ 
O.P.No. of the patient,  Date and Time of collection, Type of sample and 
Name of the ward and brought to the laboratory and processed 
immediately. 
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PROCESSING OF SAMPLES: 
Blood: BHI broth containing Blood samples were incubated at 37ÛC for 18-24hours 
after which the broth which showed turbidity were sub cultured onto the following 
media using sterile technique. 
1. Nutrient Agar 
2. MacConkey Agar 
3. Blood Agar 
 The broths which were clear were kept for further incubation for 5-7 days 
and regarded as negative for growth if it appears clear even after 48 hours of 
incubation. 
Urine: The urine specimens were centrifuged at 3000 rotaitons per minute for 5 mts. 
The sediment was used for direct Gram stain and for inoculating into the culture 
media and incubation was done at 37ÛC for 18-24 hours aerobically. 
Wound swab: One swab was used for direct Gram staining and the other swab used 
for inoculating into solid culture media and incubation was done at 37ÛC for a period 
of 18-24 hours aerobically. After this initial processing the swabs were kept in 
glucose broth and after overnight incubation the glucose broth was observed for 
turbidity and if the culture plates showed no growth after overnight incubation a 
repeat subculture was done from the glucose broth which contained the swabs. 
Pus, Sputum, Endotracheal fuid, Ascitic fluid and BAL: The specimens were 
processed, first by doing direct Gram staining and then inoculating into culture 
media and incubation was done at 37ÛC for a period of  18-24 hours aerobically.  
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CULTURE IDENTIFICATION: 
 The organisms were identified by colony morphology on solid media, 
Gram staining, biochemical reactions and other special identification tests. 
ISOLATION AND IDENTIFICATION: 
 Identification is mainly based on the Gram staining, Motility, colony 
morphology on Nutrient Agar, MacConkey Agar and Blood Agar.  All the catalase 
positive, oxidase positive and negative, nonlactose fermenting colonies on Mac 
Conkey agar were provisionally identified by colony morphology and pigment 
production. They were inoculated in Triple sugar iron (TSI) agar slope. The colonies 
which failed to acidify the TSI agar were considered as nonfermenters and subjected 
to the following tests. Indole, Citrate, Urease, Nitrate reduction, growth  at 42ÛC  , 
Sensitivity to Polymyxin B and following special biochemical tests and grouped 
according to P.C.Schreckenberger scheme(1) 
GRAM STAINING:  From  a  single  isolated  colony  on  Nutrient  agar  plate,  the  
smear was prepared in clean, dry, grease free slide and it was dried in air and fixed 
by heating. The smear was then flooded with 0.5% methyl violet and washed with 
water  after  1  minute.  Gram’s  Iodine  is  added  to  the  smear  and  washed  with  water  
after 1 minute. Then the smear was decolorized with one or two drops of acetone 
and immediately washed with water. Then counter stain with 1:10 diluted carbol 
fuschin and washed with water after 1 minute. The smear was then dried with 
blotting paper and viewed under oil immersion objective. Pink colored bacilli 
arranged in discrete pattern were identified as Gram Negative Bacilli. 
MOTILITY (HANGING DROP METHOD) :  A clean  cover  slip  was  taken  and  
petroleum jelly was applied to all the four corners. A drop of broth culture was 
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placed on the centre of the cover slip with the sterilized inoculating loop. The cavity 
slide is taken inverted over the cover slip with the drop so that the drop is placed in 
the centre. The slide was inverted and focused under 10x and the edge of the drop 
identified. Then, without changing the field, the focus was shifted to 40x and 
observed for the motile organisms. Either actively motile and non motile bacilli or 
coccobacilli were seen.  
BIOCHEMICAL REACTIONS: With the following tests Non fermenters were 
identified biochemically. 
Oxidase test (Disc method):  The  oxidase  disc  was  moistened  with  distilled  water  
and then the colony from nutrient agar was taken with the help of a sterile glass rod 
and applied over the disc. Deep blue or purple colour in 10 seconds was taken as 
positive test. 
Catalase test (Tube method): 2-3 ml of 3% Hydrogen peroxide was taken in a 
clean test tube. Few colonies of the test organism were taken from the culture plate 
with a sterile glass rod and immersed in the Hydrogen peroxide solution. Brisk 
effervescence within ten seconds was considered as catalase positive. 
TSI (Triple sugar iron medium): An isolated colony from the culture plate was 
taken with a straight wire loop and stabbed into the butt portion of the TSI medium, 
withdrawn and streaked in a zig-zag manner over the slant portion and incubation 
was done at 37ÛCfor 18-24 hours. The observation of alkaline change over the butt 
portion and alkaline change over slant portion is identified as a non-fermenter. 
Citrate utilization test: The well isolated colony from the culture plate was taken 
with a straight wire loop and inoculated into the Simmon’s citrate medium and 
incubation was done at 37ÛC for 18-24 hours. The colour change from green to blue 
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colour or the growth of colonies on the streak line was considered as positive citrate 
utilization test. 
Oxidation-fermentation (O/F ) test : Two tubes of O.F medium were inoculated 
with the organism isolated from Nutrient agar plate by stabbing 3-4 times half way 
to  the  bottom  of  the  tube  .One  tube  was  promptly  covered  with  a  layer  of  sterile  
melted paraffin  to a depth of 5-10 mm, leaving the other tube open to air. Both the 
tubes were incubated at 35ÛC for upto 30 days.  In case of oxidative metabolism, 
yellow color appears along the upper one fourth of the medium in the tube where no 
oil overlay was done. In case of fermentative organisms yellow color develops in 
both the tubes. 
CONTROL 
Glucose fermentation : Escherichia coli 
Glucose oxidation  : Pseudomonas aeruginosa 
Non saccharolytic : Alcaligenes species. 
Nitrate reduction test: The nitrate broth was inoculated with a loop full of the test 
organism isolated in pure culture on agar medium and incubation was done at 35ÛC 
for 18-24 hours. At the end of incubation, add 1 ml of Nitrate A (alpha - 
Naphthylamine and 5 N 30% Acetic acid) and Nitrate B (Sulphanilic acid and 5 N 
30% Acetic acid) reagent in that order. The development of red colour within 30 
seconds after adding the reagents indicated a positive nitrate reduction test. If no 
colour developed after addition of reagents, zinc dust was added to confirm a true 
negative reaction. 
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Growth at variable temperature: The culture from a young agar slope was 
inocualted onto two Nutrient agar plates and was incubated at 37°C and at 42°C 
respectively. The presence/absence of growth at two different temperatures was used 
in the species identification test for Pseudomonas aeruginosa and Acinetobacter 
baumanii. 
Decarboxylation of lysine, ornithine and arginine dihydrolase test (1): 
Decarboxylases are a group of specific enzymes which react with carboxyl portion 
of aminoacid forming alkaline reacting amines. The reaction is decarboxylation. 
Each enzyme is specific for Lysine, Arginine and Ornithine. The lysine and 
ornithine reactions are truly decarboxylase tests but arginine reaction is now more 
correctly recognized as dihydrolase test. 
Procedure: The organism was inoculated in four tubes containing Moller 
decarboxylase medium. One has the basal medium without aminoacid for control. 
Other three tubes had Lysine, Arginine and Ornithine each. All tubes were overlaid 
with liquid paraffin upto 4mm. All were incubated at 37oC for 24 hours. 
The control tube turned yellow indicating that the organism is viable and the test 
medium turning blue purple indicating positive result. 
O–nitrophenyl ß – D galactopyranoside: A dense suspension of the test organism 
grown in TSI agar was prepared in saline. About 1 drop of toluene was added to the 
suspension and 0.2ml of ONPG solution was added to the suspension and incubated 
at 37 oC ß-galactosidase producing organism show yellow color after 1 hour or 18-
24 hours incubation. 
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 Acetamide agar: The  slant  was  inoculated  with  a  portion  of  isolated  colony  and  
incubated at 37 oC overnight and was observed for color change from green to blue 
Tubes with negative result were further incubated for 7 days. 
 Gelatin liquefaction test: Gelatin breakdown can be demonstrated by 
incorporating it in a buffered nutrient agar, growing the culture and then flooding the 
medium with mercuric chloride that differentially precipitates either gelatin or its 
breakdown products.causing opacity in the medium with clear zones around gelatin-
liquefying colonies. 
Other biochemical tests done are:  Indole production, MR/VP test, Mannitol 
fermentation, Urea hydrolysis, Aesculin hydrolysis were all negative. 
ANTIMICROBIAL SUSCEPTIBILITY TESTING: 
Disc diffusion method: 
 Antimicrobial susceptibility was performed for all the isolates by 
modified Kirby -Bauer disc diffusion method using cation adjusted Mueller-Hinton 
agar plate. Three to four colonies were suspended in peptone water and were 
incubated for two hours at 37ºC, so as to get the organism in the logarithmic phase. 
The density of the suspension was standardized with peptone water, visually 
equivalent to 0.5 McFarland units. Within 15 minutes of preparation of the 
suspension,  a  sterile  cotton-wool  swab  was  dipped  into  the  suspension  and  the  
surplus was removed by rotating the swab against the side of the test tube. With this 
swab, the agar plate was inoculated by streaking of the swab over the entire surface 
of the plate in three directions so as to obtain a lawn culture. After brief drying, the 
antibiotic  disc  was  placed,  5  on  each  plate.  All  the  batches  of  antibiotics  were  
quality checked as per standard guidelines. The control strains used were E.coli 
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ATCC 25922 and Pseudomonas aeruginosa ATCC 27853. Overnight broth culture 
compared  to  0.5  McFarland’s  was  used  as  inoculum.  After  incubation  at  37oC for 
16-18 hrs, zone of inhibition was noted. Results were interpreted according to CLSI 
standard.Multidrug resistant (MDR) isolates of the nonfermenters were estimated 
MDR isolate was defined as resistant to three or more drugs of therapeutic 
relevance.The panel of drugs used for antimicrobial sensitivity testing was as 
follows;  
ANTIBIOTIC DISCS 
 
ZONE SIZE (mm) 
Resistance 
(mm/less) 
Intermediate 
(mm) 
Sensitive 
(mm/more) 
Cefotaxime(30 µg) 14 15-22 23 
Ceftazidime (30 µg) 14 15-17 18 
Amikacin (30ȝg) 14 15-16 17 
Gentamycin (10ȝg) 12 13-14 15 
Ciprofloxacin(5ȝg) 15 16-20 21 
Ofloxacin (5ȝg) 12 13-15 16 
Piperazillin / 
Tazobactum 100/10ȝg) 
17 18-20 21 
Trimethoprim/ 
Sulfamethoxazole 
(1.25/23.75ȝg) 
 
10 
 
11-15 
 
16 
Imipenem (10ȝg) 18 19-21 22 
Meropenem (10ȝg) 14 15-17 18 
Polymyxin B (300U) 10 - 14 
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x Interpretations were made using the Clinical and Laboratory Standards 
Institute, USA guidelines (January 2014, M100-S24- Volume 34 No.1, 
Table 2B-2, Page 62/63). 
x Journal reference was used for Polymyxin B and Colistin Disc diffusion 
standards as no CLSI guidelines exist for the same.(14,81) 
DETECTION OF ANTIMICROBIAL RESISTANCE MECHANISMS: 
Phenotypic Method: 
 All the isolates which were included in this study were subjected to 
Carbapenemase screening test using Imipenem and Meropenem disc, and ESBL 
screening test using Cefotaxime and Ceftazidime discs. The screen test positive 
isolates were subjected to respective confirmatory tests using appropriate antibiotic 
discs that were quality checked. 
DETECTION OF EXTENDED SPECTRUM ß -LACTAMASES (11,71,72) 
 All the nonfermenters that were resistant to cefotaxime and or ceftazidime 
were tested for Extended Spectrum of ß -lactamases.by the following methods: 
Phenotypic confirmation test with Cephalosporin/clavulanate combination 
disks.(72) 
 This  was  done  as  recommended  by  CLSI.   Mueller  Hinton  Agar  plates  
were swabbed with test organism having the turbidity equivalent to 0.5 Mc 
Farland’s standard. Aseptically cefotaxime disk (30mg), cefotaxime – clavulanic 
acid (30mg/10mg) ceftazidime (30mg) & ceftazidime clavulanic acid (30mg/10mg) 
were placed on surface of agar. The plates were incubated at 350C for 16-18 hours 
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and diameter of zone of inhibition produced was recorded. A 5mm increase in zone 
diameter for combination disc than that when tested alone confirmed the presence of 
ESBL production. 
 ATCC Escherichia coli 25922 & Klebsiella pneumoniae ATCC 700603 
were used as negative and positive control respectively. 
DETECTION OF METALLOBETALACTAMASE PRODUCTION IN 
ACINETOBACTER SPP., BY PHENOTYPIC METHODS:      
Carbapenamase detection:  
 The isolates which were resistant to Imipenem and Meropenem by disc 
diffusion method as per CLSI guidelines was used as the indicator for 
carbapenamase production and tested for Oxacillinase, Metallo betalactamases (82,83) 
Screening and confirmation of MBLs: 
 The Acinetobacer isolates which were found to be resistant to Imipenam, 
Meropenem by Kirby - Bauer disc diffusion method were selected. The resistant 
isolates were determined and subjected to various phenotypic detection methods 
such as Combined disc diffusion Test,  Double disc synergy test and  Modified 
Hodge Test and confirmed by genotypic method i.e, PCR. 
Common initial steps – Inoculum preparation:  
1. 3-5 colonies of the strain to be tested were touched from 24 hour 
culture plate with a straight wire loop and transferred to sterile 
peptone water and incubation was done at 37ÛC and turbidity adjusted  
to 0.5 McFarland standard. 
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2. A lawn culture was made on cation balanced Mueller Hinton agar 
plate with a sterile cotton swab using the inoculum. (Excess broth 
was  expressed  by  rotating  the  swab  against  the  inner  side  of  the  
suspension tube before inoculation.) 
3. Inoculum was then allowed to dry for 15 minutes before applying the 
antibiotic disc. 
Preparation of EDTA solution: (78) 
 0.5 M EDTA solution was prepared by dissolving 186.1g of disodium 
EDTA.2H2O in 1000 ml of distilled water and its pH was adjusted to 8.0 by using 
NaOH. The mixture was then sterilized by autoclaving. EDTA solution was added 
on Imipenem and Meropenem discs to obtain a desired concentration of 750 ȝg per 
disk.  
Combined Disc Diffusion Test (CDDT): 
 The strain to be tested was inoculated onto MHA plate as suggested 
by the CLSI. Two (10ȝg) Imipenem or Meropenem discs were placed 
on  the  plate  at  the  distance  of  20mm  and  10  ȝl  of  0.5  M  EDTA  
solution was added to one of them to obtain the desired concentration 
(750 ȝg ).  
 After18 hours of incubation, the zone diameter of Imipenem, 
Meropenem and Imipenem EDTA, Meropenem EDTA discs were 
compared. The increase in inhibition zone with Imipenem EDTA, 
Meropenem with EDTA disc 5mm than the Imipenem, Meropenem 
disc alone was considered as MBL positive. 
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Double Disc Synergy Test (DDST): 
 Lawn culture of the test organism was prepared over Mueller-Hinton 
agar plate as per CLSI guidelines. 
 A plain sterile disc was kept 20 mm apart from either Imipenem or 
Meropenem (10µg) disc. 
 5  µl  of  EDTA  was  added  to  plain  disc  and  incubation  was  done  at  
37ÛC overnight. 
 Presence of an extended zone from Imipenem or Meropenem disc 
towards EDTA was interpreted as positive. 
Modified Hodge Test (MHT):  
 ATCC E.coli 25922 inoculum was prepared in 0.5 Mc Farland 
standards & lawn culture made on Mueller-Hinton agar plate. 
 Meropenem or Ertapenem disc kept in the centre of the lawn. 
 Colonies  of  Imipenem and Meropenem resistant  isolates  were  taken  
&  streaked  from  edge  of  the  disc  to  edge  of  the  plate  &  incubation  
was done at 37° C over night. 
 The length of the streak should be 20 to 25mm.(84,85) 
 Interpretation: 
 The formation of a clover leaf like indentation along the test strains 
indicates   carbapenemase production. 
  No enhanced growth of the test strain towards the zone of inhibition 
- negative for carbapenamase production. 
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 Quality control Organisms: 
 Positive control - K.pneumoniae ATCC BAA-1705 
 Negative control - K.pneumoniae ATCC BAA-1706 
Minimum inhibitory concentration (MIC) for detecting Meropenem Resistance 
Using Macrobroth Dilution Method: 
 MIC was  determined  for  the  isolates  which  were  showing  resistance  to  
Imipenem and Meropenem (< 18mm) by disc diffusion method. 
 The Minimum Inhibitory Concentration is the least amount of 
antimicrobial that will inhibit visible growth of an organism after overnight 
incubation. 
 MIC was determined by using Mueller Hinton broth as the medium in test 
tubes.  Serial  dilutions  of  Meropenam  were  prepared  in  distilled  water.  The  
concentrations used were 256, 128, 64, 32, 16, 8, 4, 2, 1, 0.5, 0.25, 0.125 ȝg/ml.      
A young peptone water culture of the organisms corresponding to the concentration 
of 5x105/ ml is used as inoculum. A quality control strain of Pseudomonas 
aeruginosa ATCC 27853 was included. The plate was incubated at 37oC for 16-18 
hours. 
RESULTS AND INTERPRETATION 
 MIC is expressed as the highest dilution which inhibited the growth as 
judged by the lack of turbidity in the tube. 
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MIC > 8ȝgm/ml – Carbapenam resistant, MIC< 8ȝgm/ml - carbapenam susceptible. 
Level of resistance to carbapenams is also noted. 
Interpretation: 
- MIC of ATCC control strain and the test organism was observed. 
- The lowest concentration of the antibiotic which shows clearing was 
considered as the MIC for the ATCC strain & for the test isolate. 
MIC of Meropenem(41): 
 2ȝg/ml - Susceptible 
ȝg/ml - Intermediate 
ȝg/ml - Resistant 
MOLECULAR METHOD: 
Polymerase chain reaction: 
 The isolates which were resistant to Imipenem and Meropenem by Kirby 
Bauer Disc diffusion method irrespective of phenotypic methods were subjected to 
conventional PCR for the detection of Oxacillinase gene OXA-51 and Metallo Beta 
Lactamases genes bla-IMP1 and bla-VIM1.(78,79) 
Gene Identification 
Material & Methods: 
 DNA purification kit (PureFast® Bacterial Genomic DNA purification 
kit), PCR Master Mix, Agarose gel electrophoresis consumables and Primers are 
from HELINI Biomolecules, Chennai, India. 
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2X Master Mix: 
 It  contains  2U of  Taq  DNA polymerase,  10X Taq reaction  buffer,  2mM 
MgCl2, 1ȝl of 10mM dNTPs mix and PCR additives. 
Agarose gel electrophoresis: 
 Agarose, 50X TAE buffer, 6X gel loading buffer and Ethidium bromide 
are from HELINI Biomolecules, Chennai. 
Primers 
IMP gene primer 
Product size  = 220bp 
Forward Primer - 5'-TTTTGCAGCATTGCTACCGC-3' 
Reverse primer - 5'-CACGCTCCACAAACCAAGTG-3' 
VIM gene primer 
Product size  = 442bp 
Forward Primer   - 5'-GTGCTTTGACAACGTTCGCT-3' 
Reverse primer    - 5'-TCCACGCACTTTCATGACGA-3' 
OXA-51 gene primer 
 Product size = 160bp 
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Procedure: 
1. Pellet is suspended in 200ȝl of PBS. 
2. Added 50ȝl of Lysozyme and incubated at 37ºC for 15min. 
3. 400 l  of Lysis buffer and 40ȝl of Proteinase K [10mg/ml] is added 
and gently mixed well. 
4. Incubated in water bath at 70°C for 10 min. 
5.  Transferred whole lysate into PureFast spin column and centrifuged 
at 10000rpm for 1min. 
6. Discard flow through and added 500ȝl of Wash Buffer and 
Centrifuge at 10000rpm 1 min. 
7. Discard flow through and added 500ȝl of Wash Buffer-2 and 
centrifuged at 10000rpm for 1min. Repeated wash one more time. 
8. Discarded flow through and Centrifuged column for additional 2 
minute to remove any residual ethanol. 
9. Eluted DNA by adding 100ȝl of Elution Buffer and Centrifuged for 
1min. 
10. Quality and Quantity of extracted DNA is checked by loading in 1% 
agarose gel and 1ȝl of extracted DNA is used for PCR amplification. 
PCR Procedure: 
 [25ȝl of Master Mix contains: 10X Taq buffer, 2mM Mgcl2, 0.4mM 
dNTPs mix, and 2U Proofreading Taq DNA polymerase 
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1. Reactions set up as follows; 
Components Quantity 
In PCR vial 
Master mix 
25µl 
Primer Mix      (10pmoles/µl) 1µl 
Genomic DNA 1µl 
Water, nuclease free 22µl 
Total volume 50µl 
 
2. Mixed gently and spin down briefly. 
3.  Place into PCR machine and program it as follows; 
Initial Denaturation: 94ºC for 3 min 
Denaturation:     94ºC for 1 min 
Annealing:       58ºC for 1min                  35 cycles 
Extension:        72ºC for 1min 
Final extension:72º C for 5 min 
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Loading: 
1. Prepare 2% agarose gel. [2gm of agarose in 100ml of 1x TAE buffer] 
2. Mix 8ȝl 6X Gel loading dye to each PCR vial and loaded 5ȝl of PCR 
sample. 
3. Run electrophoresis at 50V till the dye reaches three fourth distances 
and observes the bands in UV Transilluminator. 
Agarose gel electrophoresis: 
1. Prepared 2% agarose. (2gm agarose in 100ml of 1X TAE buffer and 
melted using micro oven) 
2. When the agarose gel temperature was around 60ºC, added 5ȝl of 
Ethidium bromide. 
3. Poured warm agarose solution slowly into the gel platform. 
4. Kept the gel set undisturbed till the agarose solidifies. 
5. Poured 1XTAE buffer into submarine gel tank. 
6. Carefully placed the gel platform into tank. Maintaine the tank buffer 
level 0.5cm above the gel. 
7. PCR Samples are loaded after mixed with gel loading dye along with 
10ȝl HELINI 100bp DNA Ladder. [100bp, 200bp, 300bp, 400bp, 
500bp, 600bp, 700bp, 800bp, 900bp, 1000bp] 
8. Run electrophoresis at 50V till the dye reaches three fourth distance 
of the gel. 
9. Gel viewed in UV Transilluminator and observed the bands pattern. 
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Interpretation: 
 The amplified PCR products and 100bp DNA molecular markers were 
seen as bright fluorescent bands with satisfactory controls. A 160bp corresponds to 
OXA-51, 442bp corresponds to blaVIM and 220bp corresponds to blaIMP gene. 
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RESULTS 
 A total of 110 clinical isolates of nonfermenters from various clinical 
samples such as blood, urine, sputum, endotracheal aspirate, broncho-alveolar 
lavage, wound swab and other body fluids obtained from the patients admitted to 
various clinical departments of Government Chengalpattu Medical college Hospital, 
during the period of July 2014 - June15. All the isolates were characterized to the 
species level and results were analysed.  
Table 1 Age distribution (n=110) 
Age in years Number of patients Percentage (%) 
< 10 23 20.91 
11-20 5 4.54 
21-30 21 19.09 
31-40 16 14.54 
41-50 14 12.73 
51-60 10 9.09 
>60 21 19.09 
TOTAL 110 100 
 
 Age distribution of nonfermenters was analysed which showed, majority 
of the patients were from the age group of less than 10 years of age 23(20.91%), 
followed by 21-30 years 21(19.09%) and elderly patients 21(19.09), >60 years of 
age.  
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FIGURE 1: AGE DISTRIBUTION (N=110) 
 
 
 
 
 
23
5
21
16
14
10
21
0
5
10
15
20
25
< 10 .11-20 21-30 31-40 41-50 51-60 >60
Number of patients
67 
 
 
TABLE 2.GENDER DISTRIBUTION ( n = 110) 
Sex Number Percentage (%) 
Male 72 65.4 
Female 38 34.5 
 
 Of the 110 isolates of 72(65.4%) were males and  38 (34.5%) were 
females.   
 
FIGURE 2: GENDER DISTRIBUTION (n=110) 
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TABLE 3:  DISTRIBUTION OF SAMPLES ( n =110) 
Clinical sample Isolates Percentage (%) 
Pus 43 39 
Urine 20 18.1 
Wound swab 19 17.2 
 Blood 11 10 
Sputum 9 8.1 
Endotracheal aspirate 5 4.5 
Body fluids 3 2.7 
 
  Among the nonfermenters , 43 (39%) were isolated from pus, 20 (18.1%) were 
from urine,  19 (17.2%)  from wound swab, 11 (10%) from blood, 9 (8.1%)  from 
sputum, , 5 (4.5%)  from endotracheal aspirate and 3 (2.7%)  from body fluids           
FIGURE 3: DISTRIBUTION OF SAMPLES   (n=110) 
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TABLE 4: DISTRIBUTION OF CLINICAL ISOLATES  (n=110) 
Speciality Clinical isolates Percentage (%) 
Surgery 32 29.09 
Intensive care unit  22 20.01 
Medicine 16 14.55 
OG 11 10 
Urology 9 8.18 
Burns 6 5.45 
Ortho 5 4.55 
Paediatrics 4 3.64 
Otorhinolaryngology 3 2.73 
TB ward 1 0.91 
Dermatology 1 0.91 
TOTAL 110 100 
 
 Majority  of  isolates  of  nonfermenters  were  from  Surgical  ward  (40%)  
followed by ICU (20%). 
FIGURE 4: DISTRIBUTION OF CLINICAL ISOLATES (n=110) 
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Table 5: RISK FACTORS ASSOCIATED WITH INFECTIONS BY 
NONFERMENTERS (n=110) 
Risk Factors Clinical isolates Percentage (%) 
Surgery/Trauma 44 40 
ICU stay 22 20 
Prolonged antibiotic therapy 10 9.9 
Catheter and Instrumentation 9 8.18 
Diabetes Mellitus 7 6.36 
Burns 6 9.09 
Malignancy 1 0.91 
Ventillator associated pneumonia 1 0.91 
TOTAL 100 95.35 
 
 Wound swab following surgery/trauma (40%) was the major risk factor 
contributes to the infection with nonfermenters. 
FIGURE 5: RISK FACTORS 
 
44
22
10
9
7 6
1 1
Trauma
ICU stay
Amtibiotics
Catheter
Diabetes
Burns
Malignancy
VAP
71 
TABLE 6: SPECIATION OF NONFERMENTERS (n = 110) 
Clinical isolates Number Percentage (%) 
Pseudomonas aeruginosa 54 49 
Acinetobacter baumanii 36 32.7 
Acinetobacter lwoffi 8 7.3 
Stenotrophomonas maltophilia 6 5.4 
Pseudomonas stutzeri 3 2.8 
Burkholderia cepacia 3 2.8 
TOTAL 110 100 
 
 Among the nonfermenters Pseudomonas aeruginosa (49%) was the 
predominant isolate followed by Acinetobacter baumanii (32.7%), Acinetobacter 
lwoffi (7.3), S. maltophilia (5.4%), Pseudomonas stutzeri and Burkholderia cepecia 
(2.8%) 
FIGURE 6: SPECIATION OF NONFERMENTERS (n=110) 
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TABLE 7. SAMPLE WISE ORGANISM ISOLATION (n=110) 
Specimen P.aeruginosa. 
(n=54) 
P.stutzeri 
(n=3) 
B.cepacia 
(n=3) 
A.baumannii 
(n=36) 
A.lwoffi 
(n=8) 
S.maltophilia 
(n=6) 
 No. % No. % No. % No. % No. % No. % 
Pus 19 35.2 2 66.7 0 0 19 52.8 0 0 3 50 
sputum 2 3.7 0 0 3 100 2 5.6 2 25 0 0 
urine 14 25.9 0 0 0 0 2 5.6 4 50 0 0 
WS 13 24.1 0 0 0 0 4 11.1 1 12.5 1 16.7 
Blood 4 7.4 1 33.3 0 0 4 11.1 1 12.5 1 16.7 
As.fluid 1 1.85 0 0 0 0 0 0 0 0 1 16.7 
ET swab 1 1.85 0 0 0 0 4 11.1 0 0 0 0 
Pl.fluid 0 0 0 0 0 0 1 2.8 0 0 0 0 
TOTAL 54 3 3 36 8 6 
 
 Pseudomonas aeruginosa was predominantly isolated from pus, (35.2%), 
also Acinetobacter baumanni (52.8%), Acinetobacter lwoffi (25%), 
Stenotrophomonas maltophilia (50%), Pseudomonas stutzeri from pus (66.7%) and 
Burkholderia cepacia from sputum (100%). 
FIGURE 7: SAMPLE WISE ORGANISM ISOLATION (n=110) 
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TABLE 8: ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF 
NONFERMENTERS (n=110) 
 
Drugs 
Ps.aeruginosa 
(n=54) 
A.baumaniii 
(n=36) 
A.lwoffii 
(n=8 
P.stutzeri 
(n=3) 
S.maltophilia 
(n=6) 
B.cepaciaa 
(n=3) 
S % S  %  S % S % S % S % 
Gentamycin 22 40.7 18 50 4 50 1 33.3 - - - - 
Amikacin 32 59.3 26 72.2 6 80 2 66.7 2 33.3 - - 
Ciprofloxacin 23 42.6 18 50 4 50 2 66.7 6 100 1 33.3 
Ofloxacin 23 42.6 18 50 4 50 2 66.7 6 100 1 33.3 
Ceftazidime 30 56 20 55.6 6 80 2 66.7 - - 1 33.3 
Cefotaxime - - 20 55.6 6 80 - - - - 1 33.3 
Pip - Taz 39 72 26 72.2 8 100 3 100 1 16.7 1 33.3 
Cotrimoxazole - - 20 55.6 4 50 - - 6 100 3 100 
Imipenem 43 79.6 27 75 8 100 3 100 - - 2 66.7 
Meropenem 43 79.6 27 75 8 100 3 100 - - 2 66.7 
Polymyxin - B 54 100 36 100 8 100 3 100 6 100 - - 
 
 The disk diffusion susceptibility testing of the isolates shows the 
percentage of sensitivity and resistance of the isolates. Among all the isolates 
maximum resistance was recorded for Gentamycin (61.8%), Cotrimoxazole (60%), 
followed by Ciprofloxacin (50.9%) and Cefotaxime (47.3%). 
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FIGURE 8: ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF 
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TABLE 9: DETECTION OF EXTENDED SPECTRUM BETA 
LACTAMASE IN NONFERMENTERS (n=110) 
ESBL production No. of isolates Percentage % 
Positive 20 18.18 
Negative 90 81.82 
 
 Among the 110 Nonfermenter isolates screened for ESBL production and 
confirmed by CLSI phenotypic confirmatory method. 20(18.18%) isolates were 
found to be ESBL producers.(p value-0.0001 as per one proportion Z-test).ESBL 
detection is significant.  
 
FIGURE 9: ESBL DETECTION IN NONFERMENTERS (n=110) 
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TABLE 10: ESBL PRODUCTION IN NONFERMENTERS n=110 
Organism Total No. ESBL 
producers 
Percentage 
(%) 
One proportion 
Z-Test 
Ps.aeruginosa 54 9 16.7 0.0001 
A.baumanii 36 6 16.7 0.0009 
A.lwoffi 8 2 25.0 0..7516 
Ps.stutzeri 3 1 33.3 0.9885 
S.maltophilia 6 1 16.7 0.2420 
B.cepacia 3 1 33.3 0.9885 
Total 110 20 18.18  
 
 Among the isolated nonfermenters 20(18.18) were ESBL producers, 
majority 9(16.7%) were Pseudomonas aeruginosa, followed by A.baumannii 6 
(16.7%), A.lwoffi 2(25%), P.stutzeri and B.cepacia 1(33.3%) and S.maltophilia 
1(16.7%). ESBL production in Pseudomonas aeruginosa and A. baumannii is 
statistically significant (p value-0.0001 &0.0009). 
FIGURE 10: ESBL PRODUCERS IN NONFERMENTERS (n=20) 
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TABLE 11: SAMPLE DISTRIBUTION OF ESBL ( n=20) 
Clinical Sample Total No. ESBL producers Percentage (%) 
Sputum 9 4 44.4 
ET swab 5 2 40.0 
Body fluid 3 1 33.3 
Blood 11 3 27.3 
Wound swab 19 3 15.8 
Pus 43 6 14.0 
Urine 20 1 5.0 
Total 110 20 18.18 
 
 Patient with nosocomial pneumonia of sputum of clinical sample accounts 
to  44.4%  and  on  ventilator  of  ETswab  40%.  Isolates  collected  from  patients  with  
wound infection showed results for ESBL production of (29.8%). 
FIGURE 11: SAMPLE DISTRIBUTION IN ESBL PRODUCERS (n=20) 
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TABLE 12: DETECTION OF MEROPENEM RESISTANCE IN 
ACINETOBACTER ISOLATES BY DISC DIFFUSION 
METHOD (n=44) 
Pattern of susceptibility No of isolates Percentage % 
Susceptible 35 79.5 
Resistant 9 20.5 
 
 Among the 44 isolates of Acinetobacter species screened for Meropenem 
resistance by Kirby -Bauer disc diffusion method, of which 9 isolates (20.5%) were 
found to be resistant to Meropenem which is significant. (p value – 0.0015 as per 
one proportion Z-test). 
 
FIGURE 12: MBL DETECTION IN ACINETOBACTER spp., (n=44) 
 
 
Negative
79.5 %
Positive
20.5 %
79 
TABLE 13: DETECTION OF MBL PRODUCTION IN ACINETOBACTER 
SPECIES (n=44) 
Organism MBL producers Percentage 
A.baumanii (36) 9 20.5 
A.lwoffi (8) - - 
TOTAL 9 20.5 
 
Out of 44 isolates of Acinetobacter species 9(20.5%) isolates of A.baumanii. were 
MBL producers. None of the isolates of A.lwoffi were MBL producers. 
TABLE 14: SAMPLE DISTRIBUTION OF MBL ISOLATES (n=9) 
Clinical samples No. of MBL Percentage (%) 
Pus 3 33.33 
ET swab 2 22.22 
Sputum 1 11.11 
Blood 3 33.33 
Total 9 100 
 
Maximum MBL producers were from pus and blood (33.3%) samples respectively. 
FIGURE 13: SAMPLE DISTRIBUTION OF MBL ISOLATES (n=9) 
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TABLE 15: MBL DETECTION BY DIFFERENT PHENOTYPIC 
METHODS (n=9) 
Phenotypic tests Method No. of isolates Percentage% 
Positive 
Modified Hodge Test 
(MHT) 
3 33.3 
Double Disc synergy 
Test(DDST) 
4 44.4 
Combined Disc 
Diffusion 
Test(CDDT) 
5 55.6 
MHT,DDST,CDDT 3 33.3 
CDDT,DDST 4 44.4 
CDDT 1 11.1 
Negative MHT,CDDT,DDST 4 44.4 
 
 The meropenem resistance by Kirby -Bauer disc diffusion method was 
taken as the indicator for carbapenamase production and was further tested for their 
mechanisms of carbapenam resistance conferred by phenotypic methods. 
 Among the 9 isolates, Modified Hodge test was positive in 3 (33.3%) 
isolates, CDDT was positive in 5(55.6%) isolates, DDST ws positive in 4 (44.4%), 
4(44.4%) isolates were negative for all the three phenotypic methods. Out of the 9 
isolates CDDT,DDST was positive in 4 (44.4%) isolates, MHT, CDDT, DDST was 
positive in 3 (33.3%) isolates and CDDT alone was positive in 1(11.1) isolates and 
all were negative in 4 (44.4) isolate.  
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TABLE 16: MIC FOR MEROPENEM BY MACROBROTH DILUTION 
METHOD (n =9) 
MIC for 
Meropenem 
ȝg/ml) 
512 256 128 64 32 16 8 4 2 1 0.5 0.25 
A.baumannii 
(n=9) 
- 3 2 2 2 - - - - - - - 
 
Percentage 
(%) 
- 33.3 22.2 22.2 22.2 - - - - - - - 
 
 Among  the  9  Meropenem  resistant   isolates   further  tested  for  their  
meropenem minimum inhibitory concentration, All the 9 isolates have  their MIC 
values greater than 8ȝg/ml, hence they are resistant to meropenem. Among the 9 
isolates, 3(33.3%) isolates have MIC 256ȝg/ml, 2(22.2% isolates 128 ȝg/ml, another 
2(22.2%) isolates  64 ȝg/ml  and the remaining 2(22.2%) isolates have 32 ȝg/ml. 
FIGURE 14: DISTRIBUTION OF MIC VALUES FOR MEROPENEM (n=9) 
 
33.3
22.2 22.2 22.2
0
5
10
15
20
25
30
35
256ʅg/ml 128ʅg/ml 64ʅg/ml 32ʅg/ml
82 
TABLE 17: MOLECULAR DETECTION OF MBL RESISTANT GENES IN 
ACINETOBACTER BAUMANNII (n=9) 
GENES TESTED POSITIVE PERCENTAGE % 
OXA-51 3 33.3 
bla VIM 2 22.2 
bla IMP 3 33.3 
TOTAL 8 88.8 
 
 The Meropenem resistant isolates were tested for most common 
carbapenamase gene, OXA – 51 and metallo betalactamase genes VIM and IMP by 
PCR. Among the 9 Meropenem resistant isolates, 3 isolates were positive for OXA-
51 (33.3%), 2(22.2%) isolates VIM and 3 (33.3%) isolates were positive for IMP 
FIGURE 15: DISTRIBUTION OF RESISTANT GENES IN ACINETOBACTER 
SPP., (n=9) 
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TABLE 18: COMPARISON OF MBL DETECTION BY DIFFERENT 
METHODS 
Organism  
No. 
Modified 
Hodgetest 
Double disc 
Synergy test 
Combined 
disc test 
 
PCR 
+ve -ve +ve -ve + ve - ve +ve -ve 
A.baumanii 9 3 6 4 5 5 4 4 5 
Total 9 3 6 4 5 5 4 4 5 
 
 Sensitivity and specificity of Modified Hodge test for A.baumannii was 
75%  and  100%  respectively  and  for  the  EDTA  –  disk  synergy  test  sensitivity  was  
100% and specificity 80% whereas for the EDTA- combined disc test both were 
100% The differences in sensitivity and specificity between these tests were 
statistically significant (p<0.01 by chi-square test). 
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FIGURE 1: INFECTIONS CAUSED BY NONFERMENTING GRAM 
NEGATIVE BACILLI 
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FIGURE 2: DIRECT GRAM STAIN SHOWING PLENTY OF GRAM 
NEGATIVE BACILLI WITH PUS CELLS 
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FIGURE 3: GRAM STAINING SHOWING GRAM NEGATIVE BACILLI 
 
 
 
FIGURE 4: MACCONKEY AGAR SHOWING GROWTH OF 
PSEUDOMONAS   AERUGINOSA 
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FIGURE 5: BLOOD AGAR SHOWING GROWTH OF PSEUDOMONAS 
AERUGINOSA 
 
 
 
FIGURE 6: CETRIMIDE AGAR SHOWING GROWTH OF PSEUDOMONAS 
AERUGINOSA 
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FIGURE 7: CATALASE TEST – POSITIVE 
 
 
 
FIGURE 8: OXIDASE TEST – POSITIVE (DISC METHOD) 
 
 
 
 
 
 
 
 
89 
FIGURE 9: BIOCHEMICAL REACTIONS OF PSEUDOMONAS 
AERUGINOSA 
 
 
 
FIGURE 10: ANTIBIOGRAM OF PSEUDOMONAS AERUGINOSA 
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FIGURE 11: GROWTH OF PSEUDOMONAS STUTZERI ON MAC CONKEY 
AGAR 
 
 
 
FIGURE 12: BIOCHEMICAL REACTIONS OF PSEUDOMONAS STUTZERI 
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FIGURE 13: ANTIBIOGRAM OF PSEUDOMONAS STUTZERI 
 
 
 
 
FIGURE 14: BIOCHEMICAL REACTIONS OF STENOTROPHOMONAS 
MALTOPHILIA 
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FIGURE 15: ANTIBIOGRAM OF STENOTROPHOMONAS MALTOPHILIA 
 
 
 
 
FIGURE 16: GRAM STAIN SHOWING BURKHOLDERIA CEPACIA 
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FIGURE 17: BIOCHEMICAL REACTIONS OF BURKHOLDERIA CEPACIA 
 
 
 
FIGURE 18: ANTIBIOGRAM OF BURKHOLDERIA CEPACIA 
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FIGURE 19: DIRECT GRAM STAIN SHOWING GRAM NEGATIVE 
COCCO BACILLI 
 
 
 
FIGURE 20: GRAM NEGATIVE COCCO BACILLI IN CULTURE SMEAR 
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FIGURE 21: GROWTH OF ACINETOBACTER SPECIES ON MAC 
CONKEY AGAR 
 
 
 
FIGURE 22: GROWTH OF ACINETOBACTER SPECIES ON BLOOD 
AGAR 
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FIGURE 23: GROWTH OF ACINETOBACTER SPECIES ON 
CHOCOLATE AGAR 
 
 
 
FIGURE 24: BIOCHEMICAL REACTIONS OF ACINETOBACTER 
BAUMANNII 
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FIGURE 25: BIOCHEMICAL REACTIONS OF ACINETOBACTER 
LWOFFII 
 
 
 
FIGURE 26: ANTIBIOGRAM OF ACINETOBACTER SPECIES 
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FIGURE 27: MIC OF MEROPENEM - MACROBROTH DILUTION 
METHOD 
 
 
 
FIGURE 28: HODGE TEST FOR OXACILLINASE DETECTION 
 
 
 
             Meropenem resistant Isolate 2 – MHT Positive, Isolate 1 – Negative 
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FIGURE 29: IMIPENEM-EDTA COMBINED DISC TEST FOR MBL 
DETECTION 
 
          
I – Imipenem IE – Imipenem EDTA 
 
FIGURE 30: DOUBLE DISK SYNERGY TEST FOR MBL DETECTION 
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FIGURE 31: PHENOTYPIC CONFIRMATORY METHOD FOR ESBL 
 
 
 
FIGURE 32: PCR FOR IMPGENE 
 
 
Isolate No.-1, 2, 3 Positive  LD-DNA Ladder   NC- Negative Control  
 
101 
FIGURE 33: PCR FOR VIM GENE 
 
 
Isolate No.-2, 4 Positive  LD-DNA Ladder   NC- Negative Control  
 
FIGURE 34: PCR FOR OXA-51 GENE 
 
Isolate No.-1, 3, 4 Positive  LD-DNA Ladder   NC- Negative Control  
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DISCUSSION 
 Non fermenting Gram Negative bacilli (NFGNB) are being isolated with 
increasing frequency from clinical specimens and treatment failure due to their 
multidrug resistance in recent years has led to the interest in the present study. 110 
clinical isolates of non fermenting Gram negative bacilli isolated from various 
clinical samples like pus, urine, endotracheal aspirates, blood, sputum, body fluids 
and were evaluated for their role in infections in hospitalised patients including the 
characteristics of their drug resistance. 
 This  Cross  Sectional  study  was  conducted  in  the  Department  of  
Microbiology, Chengalpattu Medical College and hospital, Chengalpattu during the 
period of July 2014 to June 2015.The present study includes 110 clinically 
significant, consecutive, nonfermenter  isolates. 
 In this present study, observed that infections with nonfermenters were 
common in the patients of the age group ޒ 10 years 23(20.91%), followed by 
between the age group 21-30 years 21(19.09%)  and patient in advanced age of  > 60 
years 21(19.09%)  (Table 1). This would be due to weekened immune system and 
chronic disease associated with advanced age and hormonal abnormalities in (21-30) 
yrs. of age group. 
 Out of 110 isolates in this study, maximum number of isolates were from 
males (65.4%) as compared to females ( 34.5%) (Table 2) with male to female ratio 
of 1:1.9. Similar observation was made by Kirtilaxmi Benachinmardi et al. who 
observed 68 were males and 32 were females with male to female ratio of 1:2.1 with 
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maximum number of cases observed from the age group of 21-30 yrs and               
41-50yrs.(3) 
 In the present study out of 110 nonfermenters, 43(39%) were isolated 
from pus, 20 (18.1%) from urine, 19(17.2%) wound swab, 11(10%) blood, 9(8.1%) 
sputum, 5 (4.5%)  from endotracheal aspirate and 3(2.7%) from body fluids    
(Table  3). Gokale K.Shilpa et al. from Belgaum reported ,58.4% nonfermenters 
isolated from pus/wound discharge followed by blood 23%, 8.2% from urine, 4.5% 
sputum and 2.3% pleural fluid.(2) . Indian study conducted .by Kirtilaxmi et al. also 
stated the isolation rate of 21% from pus, 11% from urine, 7% from blood and 17% 
from tracheal aspirate.(3)  Kalidas Rit et al. from Kolkatta observed 27.86% from pus 
sample, 18.4%,from tracheal aspirate, 16.41% sputum and blood each and15.92% 
from urine (86). 
 In this present study maximum number of isolates were from Surgical 
wards (28.18%) followed by Intensive care unit (20.01%) and Medicine (14.55%) 
ward. (Table 4). Similar findings were reported by Anupurba et al. from India, 
higher prevalence rate of 29.9% in surgery wards. The second highest source 
observed in the present study was intensive care units (20.01%) followed by 
Medical ward (14.55%). These data clearly state the importance of the infections 
caused by NFGNB in the intensive care settings. Keertilaxmi Benachinmardi et al. 
also reported the isolation of 37% of NFGNB from intensive care units(3). Outbreaks 
of Burkholderia cepacia complex septicaemia have been documented worldwide in 
intensive care units (ICUs), oncology units and renal failure patients (64). 
 In this present study, risk factors were  present in 95% of the infections 
caused by Nonfermenters and the commonest risk factor associated was 
Surgery/Trauma (40%) followed by ICU stay (20%),  prolonged antibiotic 
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therapy(9.9%), Catheter and Instrumentation (8.18%) followed by  Diabetes mellitus 
(6.36%), Burns (9.09%) , Malignancy and Ventillator associated pneumonia 
(0.91%). (Table 5). In contrast to the study from Keertilaxmi Benachinmardi et al.,  
reported, the isolation of 37% NFGNB from intensive care units is identified as a 
risk factor due to prolonged stay (3).  The  study  is  from  Muktikesh  Dash et  al.  
reported  the significant risk factors for  infection were age 55 years (13.5%), 
admission in the hospital as inpatients, longer (7 days) duration of stay in the 
hospital (6.5%), having undergone any invasive procedures like catheterization 
(63.5%), intubation, and mechanical ventilation, and with  co-morbid conditions, 
i.e., diabetes mellitus, chronic obstructive pulmonary disease, asthma, neurologic 
impairment, congestive cardiac failure, end-stage renal disease, cancer, hepatitis and 
human immunodeficiency virus (87). A longer hospital stay in a high-risk unit, use of 
mechanical ventilation, admission as inpatient into the ICUs, and underlying co-
morbid conditions have been identified as the risk factors. 
 In  this  present  study,  the  commonest  isolates  were  Pseudomonas 
aeruginosa 54(49%) followed by Acinetobacter baumanii 36(32.7%), Acinetobacter 
lwoffi 8(7.3), S.maltophilia 6 (5.4%), Pseudomonas stutzeri and Burkholderia 
cepecia 3(2.8%)  among  the  NFGNB  (Table  6).  Kalidas  Rit  et al. also reported, 
Pseudomonas aeruginosa (50.24%) as the predominant isolate followed by 
A.baumannii (24.87%), A.lwoffi (5.47%) S.maltophilia (2.98%), Pseudomonas 
stutzeri (1.99%) and Burkholderia cepacia (6.96%) (86). In the present study, 
Pseudomonas spp., and Acinetobacter spp., were the commonest NFGNB isolated 
which correlates with the study done by Kirtilaxmi Benachinmardi et al.,(2). 
 In this present study, Among the 54 Pseudomonas aeruginosa isolated, 19 
(35.2%) were from pus, 2(3.7%) from sputum, 14(25.9%) were from Urine, 13 
(24.1%) from Wound swab, 4(7.4%) from blood, 1(1.85%) from Ascitic fluid and 
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ET swab (Table 7). Similarly Kirtilaxmi Benachinmardi et al. showed isolation rate 
of Pseudomonas aeruginosa, 15(25%) from pus, sputum and tracheal aspirate 
7(11.7%), urine 8(13.3%), and blood 1(1.7%) respectively (2). Study from Kalidas 
Rit et al. showed similar isolation of Pseudomonas aeruginosa 31(30.7%) from pus, 
20(19.8%) from sputum,18 (17.8%) tracheal aspirate,14(13.9%) from blood, and 
16(15.8%) from urine(86). 
 Because of high intrinsic resistance of different NFGNB to different 
antimicrobial agents, the value of proper identification and resistance testing is 
foremost important in a given setup to guide appropriate selection of empiric 
therapy. In this study, the antimicrobial susceptibility pattern of Ps.aeruginosa 
showed 43(79.6%) sensitivity to Imipenem and Meropenem followed by Piperacillin 
tazobactum 39 (72%), Amikacin 32(59.3%), Ceftazidime 30 (56%), Ciprofloxacin 
and Ofloxacin 23(42.6%) and Gentamycin 22 (40.7%) and Polymyxin B 54(100%). 
(Table 8). 
 Study from Gokale K.Shilpa et al. from Belgaum reported which is 
consistent with our results, that most of the isolates of Pseudomonas aeruginosa 
were sensitive to Meropenem(96.2%), followed by Ciprofloxacin (50.4%) and 
Amikacin (49.5%).(2) 
 A study conducted by Nautiyal et  al., reported all the isolated 
Pseudomonas aeruginosa were  sensitive to polymyxin B.(88) Kirtilaxmi 
Benachinmardi et  al., reported the sensitivity of Pseudomonas aeruginosa were 
Ceftazidime(60%), Gentamycin(65%), Piperacillin-tazobactum(73.3%), Imipenem 
(80%), Amikacin (83.3%), Ciprofloxacin (58.3%)(3) which  is  similar  to  the  present  
study .  
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 In the present study, Acinetobacter spp., were the second most common 
isolate among the nonfermenters, contributes to (40%). Study by Kirtilaxmi 
Benachinmardi et al.  also reported Acinetobacterspp., as the second most common 
isolate among the NFGNB.(3)  In the present study, among the 36 isolated 
Acinetobacter baumannii 19(52.8%) were predominantly isolated from pus, 2(5.6%) 
from  sputum  and  urine,  4(11.1%)  from  wound  swab,  Blood  and  ET  swab  and  
1(2.8%) from Pleural fluid (Table 7).  Muktikesh Dash et  al. reported similarly in 
his study that Acinetobacter isolates were common from pus sample (56.9%) (87).  
Kalidas Rit et  al. showed, 10 (20%) isolation were from pus and blood each, 9 
(18%) from sputum, 8 (16%) urine , (22%)11 tracheal aspirates(86).  
 In the present study, the isolates of A.baumannii (n=36) showed  27(75%) 
sensitivity to Meropenem and Imipenem followed by Amikacin and Piperacillin 
tazobactum 26(72.2%), Ceftazidime and Cotrimoxazole 20(55.6%) ,  Gentamycin 
and Ciprofloxacin and Ofloxacin 18(50%) each respectively. (Table 8).  All the 
isolates were sensitive to polymyxin B 36 (100%), similar results reported by 
Nautiyal et al.,(88) 
 Similar to the present study, Sohaila Mushtaq et al., have reported high 
(60%) resistance to cephalosporins and 50% resistance to aminoglycosides and 
quinolones.(89). Gokale K.Shilpa et  al. also reported same sensitivity pattern of 
Meropenem 90% and Ciprofloxacin 45% (2) 
 Among the 8 Acinetobacter lwoffi isolates, 2(25%) were isolated from 
pus, 4(50%) from urine and each 1(12.5%) from wound swab and blood.(Table 7). 
Similarly, study by Kalidas Rit et al. showed that among 11(5.5%) isolated A.lwoffi, 
3(27.3%) were from pus and tracheal aspirate, 2 (18.2%) sputum sample, 1(9.1%) 
blood and urine(86).  
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 In  this  present  study,  all  the  isolates  of   A.lwoffi were sensitive to 
Imipenem, Meropenem and Piperacillin tazobactum 8(100%) followed by 
Cefotaxime, Ceftazidime and Amikacin  6(80%), Gentamycin , Cotrimoxazole and 
Ciprofloxacin and Ofloxacin 4(50%) ,Polymyxin B(100%).(Table 8). Similar to the 
present study, a study conducted by Nautiyal et al.,  reported all the isolated A.lwoffi 
were 100% sensitive to polymyxin B .(88) 
 In contrast with the present study, Kirtilaxmi Benachinmardi et al., 
showed only 66.7% sensitivity to Imipenem, Piperacillin tazobactum, Ciprofloxacin, 
Gentamycin and Amikacin followed by (50%) sensitive to Cotrimoxazole and 
(33.3%) to Cefotaxime and Ceftazidime (3).  Also  similarly  reported  by  study  from  
Malini et al., showed that 100% sensitivity to Imipenem. ( 90) 
 Among the 6 Stenotrophomonas maltophilia isolated, 3(50%) were 
isolated from pus,1 (12.5%) from wound swab, blood and Ascitic fluid.(Table 7). 
Similar study from Deepak juyal et al. showed that out of 6(2.4%) 
Stenotrophomonas maltophilia isolated 4 (66.7%) were from pus, each 1(16.7%) 
from ear swab and urine (91).  
 In this present study, the antimicrobial susceptibility among the isolated 
S.maltophilia, majority were sensitive to Cotrimoxazole, Ciprofloxacin and 
Ofloxacin and Polymyxin B 6(100%), followed by Amikacin 2(33.3%) and 
Piperacillin tazobactum1 (16.7%).(Table 8). 
 Similar to the present study, a study conducted by Nautiyal et al.,  
reported all the isolated  S.maltophilia were 100% sensitive to polymyxin B .(88) 
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 Similar report was shown in a study conducted by Deepak juyal et  al., 
showed 100% sensitivity to Ciprofloxacin and Cotrimoxazole and 33.3% to 
piperacillin tazobactum and 16.67% to Gentamycin (91). 
 S. maltophilia is intrinsically resistant to most ȕ-lactams, including 
carbapenems.(64).   
 Among the 3 Pseudomonas stutzeri isolated, 2(66.7%) were from pus, and 
1(33.3%) from blood (Table 7). Similar  study  from  Kalidas  Rit et  al., showed 
isolation of Pseudomonas stutzeri of 2 (50%) from pus,1 (25%)from blood and 
urine.(86 ) 
 Among the isolated P.stutzeri (n=3),  all   were  sensitive  to  Imipenem,  
Meropenem and piperacillin tazobactum and Polymyxin B 3(100%), followed by 
Amikacin, Ciprofloxacin, Ofloxacin and Ceftazidime 2(66.7%), Gentamycin 
1(33.3%). (Table 8).Similar to the present study, study conducted by Nautiyal et al., 
reported all the isolated P.stutzeri were 100% sensitive to polymyxin B.(88) 
 Similar study from Kirtilaxmi Benachinmardi et al. showed 100% 
sensitivity to Imipenem, Piperacillin tazobactum (3). 
 In this present study, among the 3 isolated Burkholderia cepacia, all were 
(100%) from sputum sample (Table 7). In contrast to present study, Kalidas Rit et 
al. showed isolation of 5 (35.7%) from pus and, 2(1%) from sputum, Tracheal 
aspirate, Blood and Urine (86).  
 In this present study, among the isolated Burkholderia cepacia (n=3), all 
were sensitive to Cotrimoxazole 3(100%), followed by Imipenem and Meropenem 
2(66.7%), Ciprofloxacin, Ofloxacin, Cefotaxime and Ceftazidime 1(33.3%) 
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(Table8). In contrast to the present study, Kalidas  et  al. showed the sensitivity 
pattern of 92.8% to Imipenem and Cotrimoxazole, 85% to Ceftazidime and 
Ciprofloxacin, Piperacillin tazobactum 57%. 
 Burkholderia cepacia is intrinsically resistant to aminoglycosides and 
polymyxins and often develops resistance to ȕ-lactams due to the presence of 
inducible chromosomal ȕ-lactamases and altered penicillin-binding proteins. 
Antibiotic efflux pumps in Burkholderia mediate resistance to chloramphenicol, 
trimethoprim and fluoroquinolones 64).  
 Multidrug resistance is a major problem with non fermenting gram 
negative bacilli and so the infections caused by them are very difficult to be treated. 
Polymyxins are the remaining antimicrobial drug class with fairly consistent activity 
against multidrug resistant strains of nonfermenters. 
 ESBL continued to be a major challenge in healthcare institutions, hence 
knowledge about their prevalence is very essential to initiate appropriate 
antimicrobial  therapy.  In  the  present  study,  all  the  110  isolates  were  screened  for  
ESBL production and confirmed by CLSI phenotypic confirmatory method.  
20(18.18%) isolates were found to be ESBL producers. (p value – 0.0001 as per one 
proportion Z-Test) which is statistically significant.(Table 9). 
 In the present study, 9(16.7%) Pseudomonas aeruginosa, followed by 
A.baumannii 6 (16.7%), A.lwoffi 2(25%), P.stutzeri 1(33.3%) and B.cepacia and 
S.maltophilia 1(16.7%) were ESBL producers.(Table 10). While S.maltophilia and 
B.cepacia show intrinsic resistance to ß-lactams, ESBL production by P.aeruginosa 
and A.baumannii is significant. (P value of P.aeruginosa – 0.0001 and A.baumannii 
– 0.0009) which is statistically significant. In the present study, maximum sensitivity 
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among ESBL producers was seen with Piperacillin-tazobactum (100%) followed by 
Imipenem and Meropenem (90.5%)  
 Various studies showed difference in prevalence of ESBL in different 
areas.  Sinha et al., has reported 28% of ESBL in Acinetobacter spp., and 69.04% of 
it was due to A.baumannii and 30.96% was due to A.lwoffii.(53)  Loveena Oberoi            
et al., reported  (18.75%) Pseudomonas aeruginosa was ESBL producer. (11) 
 In  the  present  study,  the  maximum of  ESBL positive  isolates  were  from 
sputum sample (44.4%), followed by (40%) from ET swab, (33.3%) from body 
fluids, (27.3%) from Blood, wound swab (15.8%), pus (14%), and urine (5%). 
(Table 11). 
 In the study conducted by Loveena Oberoi et al., reported the prevalence 
of ESBL production was (35.16%) found to be maximum as compared to the other ȕ 
lactamases. Similar findings were reported in a study done by Bandekar et al. which 
showed a high prevalence of the ESBL producers (39.8%) in burns patients (13). 
These observation showed an increase in the prevalence of ESBL producing 
organisms in India. 
 In the present  study, 44 isolates of Acinetobacter species were screened 
for Meropenem resistance by modified  Kirby -Bauer disc diffusion method and 
MBLproduction by phenotypic method of which 9 isolates A.baumannii, (20.5%) 
were found to be resistant to Meropenem as well as MBL producers  (p value 0.0015 
as per one proportion Z-Test) which is significant.(Table-12&13). 
 Due to difference in antimicrobial susceptibility pattern in different 
hospitals, frequent studies are valuable in deciding most adequate therapy.  In this 
present study,  the meropenem resistance  was low (20.5%) when compared to the 
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study done by Sinha et al., where they have documented  28% of meropenem 
resistance. (18),     All  the  isolates  were  resistant  to  both  Imipenem  and  Meropenem  
(Gladstone  et  al.,) (54) Kyungwon Lee et al. from Korea reported 14.2% of MBL 
resistance in Acinetobacter spp.,(73)  Gomty Mahajan et al. reported  31.8% isolates  
were meropenem resistant(16).  But the study conducted by Richa Hans et  al., high 
resistance of 68% was observed against meropenem (74). In India MBL production 
among A.baumannii isolates has been reported as 42% (Amudhan et al.,).(78) 
 In this present study, the sample wise distribution of MBL in 
Acinetobacter species was  analysed  and  among  the  MBL  positive  isolates,   
3 (33.33%)  were in pus and blood, 2(22.22%) from ET swab, 1(11.11%) from 
sputum and prevalence of MBL is 20.5%. (Table14). In contrast to the present 
study, Kyungwon Lee et al. reported MBL producing isolates were mainly obtained 
from specimens of sputum (50.0%) and urine (29.3%) followed by blood, body 
fluids and venous catheter tip.(73) 
 Similarly, study by Sinha et al. reported maximum number of 
Acinetobacter isolates were from pus (37.14%) followed by blood (22.85%), and 
Urine (13.57%). Highest percentage of Acinetobacter was isolated from ICU 
(22.14%), followed by paediatrics (20.71%), neurosurgery (15.71%) and general 
surgery wards (12.87%).(9) 
 The 9 meropenem resistant isolates were tested by the indicator method 
(i.e) meropenem disc diffusion were proceeded for the detection of carbapenamase 
production.(9)  
 The mechanism of carbapenam resistance by beta lactamases were tested 
by the following phenotypic methods – Modified Hodge test for oxacillinase, 
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Imipenem-EDTA combined  disc  test  and  double  disc  synergy  test  for  metallo  beta  
lactamase  (Table-15).  
 Among  the  9  meropenem  resistant  isolates,  Modified Hodge test was 
positive in 3 (33.3%) isolates. This was similar to the study done by Gomty mahajan 
et al. (47.6%)(16). But MHT positivity varies between 2.2% to 71% in other studies. 
This may be due to lack of standardization of phenotypic procedures for detection of 
carbapenemase in NFGNB, as there are no standard procedures described in CLSI 
and other similar guidelines. In contrast to the present study, Shanthi Amudhan           
et al., reported MHT positivity in 94.4% of the isolates.(79)  And also study from 
Amudhan et al., reported modified Hodge test was positive in 97.4% isolates of 
A.baumannii (78) 
 In this present study, Imipenem-EDTA combined disc test (CDDT) was 
positive in 5(55.6%) isolates, Double disc synergy test (DDST ) was positive in 4 
(44.4%) , isolates. Similar to the present study, Sinha et al.,  and  Uma et al., have 
documented 60.71% and 71% of MBL respectively.(16) by CDDT. In contrast to the 
present study, Gupta et  al.,  Lee et al., and Franklin et  al. have documented 7.5%, 
14% and 16% MBL respectively.(16,73) Study from Shanthi Amudhan et al. reported 
MBL screening with EDTA was positive in 80.4%(79). Study from Amudhan et al., 
reported the metallo-beta-lactamase screening test with EDTA was positive in 
79.3% isolates.(78)  Study from Gomty mahajan et al. reported 19% of MBL 
producers by EDS test.(16) 
 The reason for the variations in MBL detection may be due to lack of 
standard procedures and variations in the expression of MBL gene.(16) 
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 Among the 9 meropenem resistant isolates, 4/9(44.4%) isolates were 
negative for all the three phenotypic methods. This shows that carbapenem 
resistance in those isolates may be due to non-expression of carbapenem resistant 
genes, altered porin channels and/or efflux pump mechanisms. 3/9 (33.3%) isolates 
were positive for all the three tests and 3/9 (33.3%) isolates were positive for both 
oxacillinase and metallo betalactamase. Out of the 9 isolates CDDT,DDST was 
positive  in  4  (44.4%)  isolates,  MHT,  CDDT,  DDST  was  positive  in  3  (33.3%)  
isolates and CDDT alone was positive in 1(11.1%) isolates and all were negative in 
4 (44.4%) isolate. Study from Richa Hans et al., reported co existence of 
Carbapenemase and MBL production was observed in 16% isolates. (74) 
 This implies that combination of several mechanisms may exist in the 
same isolate to confer carbapenem resistance.(12) 
 The meropenem resistant isolates  were  further  confirmed  by  MIC.  All  
the 9 isolates have their  MIC in the resistant range (>8ȝg/ml),  hence disc diffusion 
method correlates with MIC.(41) This shows that  regular screening for meropenem 
resistance can be done using disc diffusion method and further confirmed by MIC .  
 In this present study, among the 9 MBL isolates, MIC value of 3(33.3%) 
isolates were 256ȝg/ml, followed by 128 ȝg/ml for 2(22.2%), 2(22.2%) isolates 
have 64 ȝg/ml and the remaining 2(22.2%) isolate has 32 ȝg/ml. (Table-16).  
 Study from Sinha et al. reported MIC range of 8 and 64 ȝg/ml(9). 
Amudhan et al. has documented MIC values ranging from 8ȝg/ml to128ȝg/ml(78).  
 Maryam Noori et al. have reported meropenem MIC as high as 256ȝg/ml 
in Iran.(92) In this study, out of 9 resistant isolates 3 isolates have MIC value of 
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256ȝg/ml , indicating the prevalence of high level resistant strains among the 
isolates, which is similar to the present study. 
 In this study, the 9 isolates of A.baumannii which were resistant to 
Meropenem by Disc diffusion method were subjected to PCR for the detection of 
most  common Oxicillinase  gene  OXA-51 and  Metallo  Beta  Lactamases  genes  bla-
IMP and bla-VIM.(Table 17). 
 In this study, among the 9 Meropenem resistant isolates, all the 3 isolates 
were positive for OXA-51 (33.3%), In Indian studies, in contrast to the present 
study, the maximum OXA-51 positive isolates was reported as 83.96% in the study 
done by Amudhan et al.(17) Oxacillinases would also inactivate carbapenems, though 
they are less efficient hydrolyzers of carbapenems invitro than MBLs.(8)  
 In this present study, 2(22.2%) isolates were positive for blaVIM1 and 3 
(33.3%)  isolates  were  positive  for  blaIMP1.   Among  the  9  isolates,  one  isolate  
showed positivity of IMP,VIM and OXA-51 and two isolates showed positivity of 
IMP,OXA-51 and OXA-51 and VIM. (Table 17). 
 Study from Shanthi Amudhan et al., reported MBL genes IMP and IMP 
were detected in 51.4% of the isolates. Among these MBL producers 89 isolates 
carried VIM alone, two carried IMP alone and 1 carried both .(79)  Study from sinha 
et al., reported nine Acinetobacter isolates carried bla-IMP gene and two of these 
also carried  bla-VIM.(9) 
 In the study by K.Lee et al. from Korea reported 28.9% of MBL positive 
isolates of Acinetobacter spp. were IMP producers, showed prevalence of 71.1% of 
VIM -2 and 28.9% IMP-1of Acinetobacter spp.,(73) Similar to the present study, 
Amudhan et  al. have documented 0.86% of all three genes positive isolates.(78) 
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Similarly Sinha et al. have documented 7.14% of both VIM1 and IMP1 positive 
isolates.(9) 
 In the present study by comparing the various MBL detection methods 
with the gold standard PCR, the sensitivity and specificity of Modified Hodge test 
was 75% and 100% ,  Disc synergy test was 100% sensitve and 80% specific and for  
combined  disc  test  both  were  100%.  The  differences  in  both  sensitivity  and  
specificity between these tests were statistically significant. (Table 18). 
MANAGEMENT OF INFECTIONS BY NFGNB 
 The prevalence and sensitivity of nonfermenters often varies between 
communities, in the same community and hospitals, among different patient 
populations  in  the  same  hospital.  Faced   these  variations,  the  physician  in  clinical  
practice has the responsibility of making clinical judgments and should access to 
recent data on the prevalence and antimicrobial resistance pattern of commonly 
encountered pathogens. 
 It  is  therefore  important  to  institute  a  system  for  the  surveillance  of  
antimicrobial resistance that will involve the collection of both clinical and 
microbiological data.  
 The present study observed highest resistance of NFGNB against 
Gentamicin & Cefotaxime antibiotics which are commonly used drugs .This 
necessitates the judicious use of these antibiotics in empirical therapy. Maximum 
sensitivity was observed with newer agents like carbapenams and pipercillin-
tazobactum and Polymyxin.  
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 Moderatly sensitive to Aminoglycosides and Fluroquinolones. Major risk 
of using monotherapy is the emergence of antibiotic resistance as observed in the 
present study which showed high rate of multidrug resistance and ESBL producers.  
 Carbapenamase resistance, though not high was still observed as an 
emerging drug resistant mechanisms in the NFGNB from this hospital. Antibiotic 
therapy either empirical or documented is based upon antibiotic combination 
supplemented by the knowledge of local epidemiology of susceptibility pattern in 
choosing a suitable combination. 
 Therefore combination therapy such as piperacillin-tazobactum,  
quinolones amikacin,imipenam-amikacin would be an ideal choice of therapy on the 
basis of antimicrobial susceptibility testing as observed in this study along with an 
adequate infection control measures especially in the surgical and ICU units.(93,94) 
 The treatment of Acinetobacter infections remains a great challenge 
because resistance to aminoglycosides, cephalosporins and quinolones has 
substantially increased worldwide. Carbapenems are the drug of choice for MDR 
Acinetobacter infections, for ESBL producing isolates, but resistance to 
carbapenems by the production of carbapenamases and various other mechanisms 
has limited the therapeutic options.(95)  
 Because of increasing carbapenem resistance and limited therapeutic 
options available, the old antibiotic colistin is being used more extensively 
nowadays, but resistance to colistin has also been reported.(96).  In  my study  all  the  
isolates were sensitive to Polymyxin B. 
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 Hence currently combination therapy like meropenem with tigecycline 
and colistin with sulbactum or rifampicin are being tried in the treatment of 
Acinetobacter spp., infection(97). 
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SUMMARY 
 This study was conducted at the Department of Microbiology, 
Chengalpattu Medical college and Hospital aimed at isolation, speciation and 
determination of antimicrobial susceptibility among the nonfermenters with 
molecular analysis of resistant genes of Acinetobacter spp., revealed the following 
findings: 
x A total of 110 clinical isolates of NFGNB from various clinical 
specimens were included in this study 
x Majority  of  isolated  nonfermenters  were  from  the  age  group  of  less  
than 10 years (20.91%) with preponderance to males (65.4%). 
x Among the nonfermenters isolated , (39%) were  from pus,  (18.1%) 
from urine,  (17.2%)  from wound swab, (10%) blood, (8.1%) 
sputum,  (4.5%) endotracheal aspirate and (2.7%)  from body fluids 
x Majority of isolates of nonfermenters were from Surgical ward (40%) 
followed by ICU (20%). 
x The major risk factor contributes to infection with nonfermenters was 
surgery/trauma (40%) 
x Among the isolated nonfermenters Pseudomonas aeruginosa (49%) 
was the predominant isolate followed by Acinetobacter baumanii 
(32.7%), Acinetobacter lwoffi (7.3%), S. maltophilia (5.4%), 
Pseudomonas stutzeri and Burkholderia cepecia (2.8%). 
x Pseudomonas aeruginosa (35.2%). Acinetobacter baumanni (52.8%), 
Acinetobacter lwoffi (25%), Stenotrophomonas maltophilia (50%), 
Pseudomonas stutzeri (66.7%)   were isolated predominantly from 
pus and Burkholderia cepacia from sputum (100%). 
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x The antimicrobial susceptibility pattern of the isolated nonfermenters 
revealed maximum resistance was recorded for Gentamycin (61.8%), 
Cotrimoxazole (60%), followed by Ciprofloxacin (50.9%) and 
Cefotaxime (47.3%). 
x All the isolates were sensitive to Polymyxin B (100%) followed by 
Imipenem and Meropenem (75.5%). 
x Extended spectrum betalactamase (ESBL) was observed in 
20(18.18%) isolated nonfermenters. (16.7%) pseudomonas 
aeruginosa, followed by A.baumannii (16.7%), A.lwoffi (25%), 
P.stutzeri (33.3%) and B.cepacia and S.maltophilia (16.7%) were the 
ESBL producers. 
x Maximum of ESBL positive isolates were from sputum (44.4%), 
followed by (40%) ET swab, wound swab (29.8%). 
x Among the 44 isolated Acinetobacter species screened for 
Meropenem resistance by modified Kirby -Bauer disc diffusion 
method, 9 isolates of A.baumannii (20.5%) were found to be resistant 
to Meropenem. 
x All  the  9  Meropenem  resistant   isolates  of   A.baumannii had  their 
MIC above 8 ȝg/ml. (ȝg/ml –Resistant) 
x Maximum MBL producers were from pus and blood (33.3%) samples 
respectively 
x Combined  disc  diffusion  test  was  a  better  method  of  detection  of  
metallobetalactamase production phenotypically with a sensitivity 
and specificity of 100%. 
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x Molecular characterization of 9 MBL Acinetobacter baumannii 
revealed 3 (33.3%)   OXA-51 gene, 3 (33.3%) blaIMP gene and 
2(22.2%) blaVIM gene positivity. 
x There is multiple gene expression for 3 (60%) isolates indicating the 
occurrence of increasing MBL resistance among Acinetobacter 
baumannii. 
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CONCLUSION 
 Observations from this present study showed that the aerobic NFGNB 
which are usually considered as contaminants are now emerging as important 
nosocomial  pathogens.The  various  clinical  samples  from  which  they  were  isolated  
proved  their  existence  in  all  the  sites  leading  to  a  range  of  diseases.  Different  
antimicrobial susceptibility pattern and multidrug resistance exhibited by 
nonfermenters  pose  a  great  problems  in  treating  these  infections.  ESBL  and  MBL  
production by these organisms lead to high morbidity and mortality and we were left 
with  the  only  option  of  treating  them  by  potentially  toxic  drugs  like  Colistin  and  
Polymyxin B. Care in detection, evaluation of effective antibiotic option, judicious 
use of antibiotics by instituting antibiotic policy and infection control measures will 
help to fight against these multidrug resistant nonfermenters in the effective 
managementof patients. 
 Acinetobacter species are the second most common nonfermenter isolated 
from clinical specimens next to Pseudomonas species. The infections caused by 
multidrug resistant Acinetobacter that are capable of producing various beta 
lactamases are associated with significant morbidity and mortality. Hence 
Acinetobacter has been added to the list of significant microbial challenges in the 
current era. 
 A.baumannii was the most common species isolated and  most resistant 
when compared to other Acinetobacter species and there was a significant difference 
in their antimicrobial susceptibility pattern. 
 Carbapenems remain the drug of choice for the MDR Acinetobacter 
infections. But resistance to carbapenems occur due to production of various beta 
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lactamases is of great concern as they are encoded by genes which are horizontally 
transmissible. There is difference between phenotypic and genotypic methods in the 
sensitivity of detection of carbapenamases where genotypic methods are more 
sensitive and remain the gold standard. 
 The occurrence of MBL is not only a therapeutic issue, but poses serious 
concern for infection control as well. Hence the treatment option is left with the 
polymyxin-B and colistin which are highly nephrotoxic and neurotoxic. In this 
study, all the isolates were sensitive to polymyxin-B. 
 The present need is that all the health care institutions should have a 
coordinated effort to curtail inappropriate use of antibiotics, their own antimicrobial 
stewardship program, and vigilant detection of resistant non fermenters, regular 
surveillance and infection control protocols to control the increasing incidence of 
highly resistant nonfermenters. 
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APPENDIX-I 
 ABBREVIATIONS 
NFGNB - Nonfermenting gram negative bacilli 
Ps.aeruginosa - Pseudomonas aeruginosa 
Ps.stutzeri  - Pseudomonas stutzeri 
A.baumanii  - Acinetobacter baumanii 
A.lwoffii  - Acinetobacter lwoffii 
S.maltophilia - Stenotrophomonas maltophilia 
B.cepacia  - Burkholderia cepacia 
Mac plate  - MacConkey plate 
MHA  - Mueller Hinton Agar 
MDR  - Multidrug resistant 
ESBL  - Extended Spectrum Of Betalactamases 
MBL  - Metallobetalactamases 
ATCC  - American Type Culture Collection 
CLSI  - Clinical & Laboratory Standards Institute 
MIC  - Minimum Inhibitory Concentration 
PCR  - Polymerase chain reaction 
CDDT  - combined discdiffusion test 
DDST - Double disc synergy test 
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MHT  - Modified Hodge Test 
EDTA  - Ethylene Diamine Tetra acetic Acid 
OXA-23  - Oxacillinase beta lactamase 
bla-IMP  - Imipenamase metallo beta lactamase 
bla-VIM  - Verona integron encoded metallo beta lactamase 
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APPENDIX II 
 PREPARATION OF GRAM STAIN 
 GRAM STAIN REAGENTS 
 1. Methyl violet - Primary stain 
 Methyl violet 10 g 
 95% ethyl alcohol 100 ml 
     Distilled water 1 L 
 2.  Gram’s Iodine – Mordant 
      Iodine 10 g 
 Potassium iodide 20g 
      Distilled water 1 L 
 3.  Acetone - Decolouriser 
 4.  Dilute Carbol Fuchsin - Counter stain 
     Basic fuchsin 0.3g 
     95% Ethyl alcohol 10 ml 
     Phenol crystals, melted 5 ml 
 Distilled water 95 ml 
 Basic fuchsin was dissolved in alcohol.5 % phenol solution was added 
and was allowed to stand overnight. Then the solution filtered through coarse filter 
paper.  
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 MEDIA USED: 
 PREPARATION OF MAC KONKEY AGAR 
 Contents: 
Sodium taurocholate 5.0 g 
Peptone 20.0 gm 
Sodium chloride 5.0 g 
Lactose 10.0 g 
Agar 15.0 g 
Distilled water 1000 ml 
Neutral red (2% solution in 50% ethanol) 3.5 ml 
 5 g sodium taurocholate or bile salts, 20 g of peptone, 5 g sodium 
chloride and 15 g agar were mixed with 1000 ml water. 
 Steamed until the solids were dissolved. 
 Cooled to about 50ÛC, and at this temperature the reaction was 
adjusted to pH 7.5 to 7.8. Autoclaved at 121ÛC for 15 minutes and 
filtered while hot through a good grade of filter paper, or a plug of 
cotton wrapped in gauze placed in the funnel. 
 The reaction of the filtrate was adjusted to pH 7.3 at 50ÛC or pH 7.5 
at room temperature. 10 gm lactose and 3.5 ml of 2% solution of 
neutral red in 50% ethanol were added. Mixed thoroughly and 
distributed in flasks and sterilized in the autoclave at 121ÛC for 15 
minutes. 
  For  use,  melted  in  the  steamer,  poured  into  sterile  petri  dishes  and  
allowed to set. 
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 PREPARARION OF BLOOD AGAR 
 Nutrient agar 100 ml 
 Sheep blood (defibrinated) 10 ml 
 The sterile nutrient agar was melted by steaming and cooled to 45ÛC. 
 5% -10% sheep blood was added aseptically with constant shaking. 
 The blood was mixed with molten nutrient agar thoroughly but 
gently, to avoid froth formation.To remove the bubbles, media was 
flamed. 
 Immediately poured into petri dishes and allowed to set. 
 PREPARATION OF MUELLER – HINTON AGAR   
 Contents: 
Beef extract 2.0 gm 
Acidicase Peptone 17.5 gm 
Starch 1.5 gm 
Agar 17.0 gm 
Distilled water 1000 ml 
Final pH 7.4 + 0.2 
 Dissolve the ingredients in one liter of distilled water. Mix thoroughly. 
Heated with frequent agitation and boiled for one minute. Dispensed and sterilized 
by autoclaving at 121ÛC for 15 minutes. Should not be over heated. 
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 ACETAMIDE AGAR  
Ingredients: 
Magnesium Sulphate : 0.2g 
Ammonium dihydrogen Phosphate : 1g 
Pottasium monohydrogen phosphate : 1g 
Sodium Chloride : 5g 
Acetamide : 10g 
Bromothymol blue solution : 6.4ml 
Agar : 15g 
Final pH : 6.9 
Distilled water : 1 litre 
 The ingredients are mixed and pH adjusted to 6.9, dispensed into screw 
cap tubes and sterilized at 1210C for 15 min. The medium was allowed to cool in a 
slant. The slant was inoculated with a portion of isolated colony and incubated at 
370C overnight and was observed for color change. Tubes with negative result were 
further incubated for 7 days. 
Control 
Positive control : Pseudomonas aeruginosa 
Negative Control  : Stenotrophomonas maltophilia 
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 MEDIA REQUIRED FOR BIOCHEMICAL IDENTIFICATION: 
1. Catalase Test: 
 3% hydrogen peroxide. 
2. Oxidase Reagent: 
 Tetra methyl p-phenylene diamine dihyrochloride- 1%aqueous solution. 
3. Indole test: 
 Kovac’s reagent 
 Amyl or isoamyl alcohol 150ml 
 Para dimethyl amino benzaldehyde 10g 
 Concentrated hydrochloric acid 50ml 
 Dissolve the aldehyde in the alcohol and slowly add the acid. Prepare in 
small quantities and store in the refrigerator. Shake gently before use. 
4. Simmon’s Citrate Medium: 
 Koser’s medium 1 ltr 
 Agar 20g 
 Bromothymol blue 0.2% 40ml 
 Dispense, autoclave at 121°C for 15 min and allow to set as slopes. 
5. riple Sugar Iron medium: 
 Beef extract 3g 
Yeast extract 3g 
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Peptone 20g 
Glucose 1g 
Lactose 10g 
Sucrose 10g 
Ferric citrate 0.3g 
Sodium chloride 5g 
Sodum thiosulphate 0.3g 
Agar 12g 
Phenol red 0.2% solution 12ml 
Distilled water 1 Lt 
 Heat  to  dissolve  the  solids,  add  the  indicator  solution,  mix  and  tube.  
Sterilize at 121°C for 15 min and cool to form slopes with deep butts. 
6. Mannitol motility medium 
Agar 5g 
Peptone 1g 
Potassium nitrate 1g  
Mannitol 2g 
Phenol red indicator 
Distilled water l000ml 
pH 7.2 
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7. Nitrate medium: 
 Potassium nitrate 0.2g 
 Peptone 5g 
 Distilled water 1000ml 
 The above contents were mixed and tubed in 5 ml amounts and 
autoclaved at 121Ûc for 15 minutes. 
Test reagent: Solution A: 8 g of sulphanilic acid was dissolved in 1 L of acetic acid 
5  mol/litre  Solution  B:5  g  of  alpha-naphthlamine  in  1  L  of  acetic  acid  5  mol/litre.  
Immediately before use, equal volumes of solutions A and B were mixed to get the 
test reagent. 
8. Decarboxylase media: 
 Moller decarboxylase broth base: 
Peptone 5 g 
Beef extract 5 g 
Bromocresol purple 0.01 g 
Cresol red 0.005 g 
Glucose 0.5 g 
Pyridoxal 0.005 g 
Distilled water 1 lit. 
Final pH 6 
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Aminoacid: 
 Add 10 g of the levo form of the aminoacid for 1000ml.mix and dispense 
in sterile tubes. 
9. Hugh & Leifson’s Oxidation –Fermentation test: 
Peptone 2g 
Sodium chloride 5g 
D-glucose 10g 
Bromothymol blue 0.03g 
Agar 3.0g 
Dipotassium phosphate 0.30g 
Distilled water 1lit. 
pH =7.1 
 Basal medium is autoclaved.1% of sterile sugar solutions is added to the 
basal medium. Dispense into sterile test tubes without slant. 
10. Malonate Utilization test: 
Yeast Extract 1 g 
Ammonium sulphate 2 g 
Dipotassium phosphate 0.6 g 
Potassium phosphate 0.4 g 
Sodium chloride 2 g 
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Sodium malonate 3 g 
Bromothymol blue 0.025g 
Distilled water 1 lit. 
Adjust the pH to 7.4. Sterilize by autoclaving at 121oC for 15min. 
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ANNEXURE I
 
135 
 
 
 
136 
ANNEXURE  II 
                                  DATA COLLECTION PROFORMA 
1. Case No. : 
2. Name and address of the patient :                                                             
3.  Age & sex : 
4.  OP & IP No : 
5.  Ward and Unit : 
6.  Date of admission : 
7. Occupation and income : 
8. Clinical diagnosis : 
9. Relevant co-existing clinical conditions/illnesses : 
10. History of presenting illness : 
11. Past history : 
12. Personal history : 
13. Treatment History : 
     (Antibiotics taken if any) 
14. Sample collected : 
15. Date of sample collection : 
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Microbiological investigation: 
1. Confirmation of the Isolate  : 
2. Speciation  : 
3. Name of the species identified : 
4. Antimicrobial sensitivity pattern : 
 Sensitive to  : 
 Resistance to  : 
5. Resistance pattern identified  : 
6. MBL gene detection by PCR  : 
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ANNEXURE III - CONSENT FORM 
PATIENT CONSENT FORM 
STUDY DETAIL: 
“CHARACTERISATION AND ANTIMICROBIAL SUSCEPTIBILITY 
PATTERN OF NON FERMENTING GRAM NEGATIVE BACILLI AND 
MOLECULAR ANALYSIS OF ACINETOBACTER SPP., FROM VARIOUS  
CLINICAL SAMPLES IN A TERTIARY CARE HOSPITAL ”  
STUDY CENTER: CHENGALPATTU MEDICAL COLLEGE & HOSPITAL, 
CHENGALPATTU 
PATIENT NAME:     PATIENT AGE: 
IDENTIFICATION NUMBER: 
PATIENT TO TICK (        )THESE BOXES  
 I confirm that I have understood the purpose of procedure for the 
above study. I have the opportunity to ask the question and all my questions 
and doubts have been answered to my satisfaction. 
 I understand that investigator, regulatory authorities and the ethics 
committee  will  not  need  my  permission  to  look  at  my  health  records  both  in  
respect to the current study and any further research that may be conducted in 
relation to it, even if withdraw from the study, I understand that my identity 
will  not  be  revealed  in  any information released to  third  parties  or  published,  
unless as required under the law. I agree not to restrict the use of any data or 
results that arise from the study. 
 I agree to take part in the above study and to comply with the 
instructions given during the study and faithfully cooperative with the study 
team and to immediately inform the study staff if I suffer from any 
deterioration in my health or wellbeing or any unexpected or unusual 
symptoms. 
 I hereby give consent to participate in this study. 
 
Signature/Thumb impression:    
Patient name and address:                                             Date: 
Signature of the investigator:            Place: 
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N ?~©I LT 
7º ]DN~L I_Q~©: "CHARACTERISATION AND 
ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF NON FERMENTING 
GRAM NEGATIVE BACILLI AND MOLECULAR ANALYSIS OF 
ACINETOBACTER SPP.,  FROM VARIOUS  CLINICAL SAMPLES IN A 
TERTIARY CARE HOSPITAL " . 
7º ]DN~L 8G  :  
Lu ]L²LTƬ} ]LNƫ  :  
Lu ]L²LTƬ} TN¢  :                                            
 ^M^Q PY~LyR M¯{¢T 7T} TTOuB <Kt 
TRtBLyR¢. JX} 8TXT I}Kv_DNXB Lu^BBY}^P}. 
<|I BXOH{IYKX^QX, <|I DyG DYtB´t :yLGXM JX} 
8TXT 8¯|¢ TQBYt ]BXRQX <}² 6PY|¢]BXz^G}. 
 8|I 7º DL|IMXB^TX, 8_I DXƫ|¢ ^M´ 7º 
^M]BX¶ ^LX¢ 8|I 7T Lu]L² M¯{¢Tƫ <}§_GN 
M¯{¢Tƫ <}§_GN M¯{¢T 6PYt_BB_R LXƫ~LI <} 6§MIY 
^I_T 8_Q <K 6PY|¢ ]BXBY^P}. 8|I 7T} ¬Q 
BY_Gt IBT_Q^NX,«_T^NX LN}L{IYt ]BXR 
M²tBMXy^G}. 
 8|I 7T Lu ]BXR ?~©t ]BXBY^P}. 8|I 7_T 
^M]BX¶ M¯{¢T 6Ht :z_M­G} 8¯~^L} <}² 
:²IYNRtBY^P}. 
 
 Lu^BLTƬ} _B]NX~L:                                                                  8G:                                                              
Lu^BLTƬ} ]LNƫ M² TQXD:    ^IIY:                                                                                      
7TXRƬ}  _B]NX~L: 
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ANNEXURE – IV  MASTER CHART 
S.
N
o 
M
ic
ro
 N
o.
 
A
ge
 
se
x 
w
ar
d 
D
ia
gn
os
is 
sp
ec
im
en
 
or
ga
ni
sm
 
G
en
ta
m
yc
in
 
A
m
ik
ac
in
 
Pi
p-
ta
z 
C
ef
at
ax
im
e 
C
ef
ta
zi
di
m
e 
Im
ip
en
em
 
M
er
op
en
em
 
Po
ly
m
yx
in
B 
O
flo
xa
ci
n 
C
ip
ro
flo
xa
ci
n 
C
ot
ri
m
ox
az
ol
e 
R
es
is
ta
nc
e 
pa
tte
rn
 
M
R
P(
M
IC
) 
M
H
T 
C
D
D
T
 
C
D
ST
 
IM
P 
V
IM
 
O
X
A
-5
1 
1 1618 2/12 Fch NICU Sepsis Blood A.bau S S S S S S S S S S S 
        2 3181 27 F OG UTI Urine A.lwofi S S S S S S S S S S S 
        3 3086 70 M Urology UTI Urine A.lwofi S S S S S S S S S S S 
        4 1103 5 Fch Paed.sur WI Pus Ps.stut R S S R R S S S S S R ESBL 
       5 3406 24 M Medicine UTI Urine Ps.aeru S S S R S S S S S S R 
        6 1086 30 M Surgery WI WS Ps.aeru S S S R S S S S S S R 
        7 1603 3/12 Fch NICU PUO Blood A.bau R S R R R R R S R R R MBL 256 + + + + + + 
8 1787 5/365 Mch NICU Sepsis Blood A.bau R S R R R R R S R R R MBL 128 
 
+ + + 
  9 3545 28 F Medicine UTI Urine A.lwofi S S S S S S S S R R S 
        10 1205 5/365 Fch NICU Sepsis ET swabA.bau R R R R R R R S R R R MBL 256 + + + + 
 
+ 
11 1221 70 M Medicine Pneumonia Sputum A.bau S S S R R S S S S S S ESBL 
       12 1219 6/365 Mch NICU Sepsis ET swabA.bau R R R R R R R S R R R MBL 256 + + + 
 
+ + 
13 1243 78 M Surgery Pyothorax Pus S.malt R R R R R R R S S S S 
        14 3944 30 F Urology UTI Urine A.lwofi R R S R S S S S R R R ESBL 
       15 3981 15 M Medicine UTI Urine Ps.aeru S S S R S S S S S S R 
        16 3486 40 M Medicine Burns WS A.lwofi S S S S S S S S S S S 
        17 1469 58 M Surgery WI Pus A.bau R R R R R R R S R R R MBL 128 
 
+ 
    18 1481 52 M Surgery WI WS Ps.aeru R S S R R R R S R R R ESBL 
       19 1595 82 M Surgery SSI Pus Ps.aeru R R R R R R R S S S R 
        20 1603 24 F OG SSI Pus Ps.aeru R S S R S S S S R R R 
        21 1605 40 M Ortho #BBLeg Pus A.bau R S R R R R R S R R R MBL 64 
      22 1641 82 M Burns Burns WS A.bau R R S R R S S S R R R ESBL 
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23 4161 24 M Urology UTI Urine Ps.aeru S S S R S S S S S S R 
        24 4417 86 M Urology UTI Urine Ps.aeru S S S R S S S S R R R 
        25 4425 35 F Urology UTI Urine Ps.aeru S S S R S S S S S S R 
        26 4497 20 M Urology Pyelo Urine Ps.aeru S S S R S S S S S S R 
        27 4551 58 M Surgery UTI Urine Ps.aeru R R S R S S S S S S R 
        28 1694 1 F NICU Burns WS A.bau S S S S S S 
 
S S S S 
        29 4631 48 F Medicine UTI Urine A.bau S S S S S S S S S S S 
        30 4815 21 F OG UTI Urine A.bau R S S S S S S S S S R 
        31 5181 23 F OG UTI Urine Ps.aeru R R S R S S S S R R R 
        32 1783 70 M Ortho Osteo Pus A.bau R S S R R S S S S S R ESBL 
       33 1784 58 F Burns Burns WS S.malt R R S R R R R S S S S ESBL 
       34 1760 20 F OG SSI Pus Ps.aeru S S S R S S S S S S R 
        35 1735 82 M Surgery WI Pus A.bau S S S S S S S S S S S 
        36 1727 30 M Surgery WI Pus Ps.aeru R S S R R S S S S S R ESBL 
       37 1694 1 F NICU Burns WS A.bau R S S S S S S S R R R 
        38 1684 30 M Ortho WI Pus Ps.aeru R S R R R S S S S S R 
        39 1665 1 M NICU Asphyxia ET swabA.bau R R S R R S S S S S R ESBL 
       40 1641 82 M Surgery DM foot Pus A.bau S S S S S S S S S S S 
        41 2465 1 F NICU Sepsis Blood Ps.aeru R R S R R S S S S S R ESBL 
       42 2412 1 M NICU Sepsis Blood Ps.aeru S S S R S S S S S S R 
        43 2355 10 F Paed PUO Blood S.malt R R R R R R R S S S S 
        44 2345 1 M PICU PUO Blood Ps.aeru R R S R R S S S R R R ESBL 
       45 2486 1 M NICU Sepsis Blood Ps.stut S S S R S S S S S S R 
        46 5324 6 M PICU UTI Urine Ps.aeru S S S R S S S S R R R 
        47 1838 70 F Surgery DM foot Pus A.bau S S S R R S S S S S S ESBL 
       48 1840 24 F Surgery WI Pus A.bau S S S S S S S S R R S 
        49 1844 33 M Surgery SSI Pus A.bau S S S S S S S S S S S 
        50 1846 54 M Medicine Ascites As.fluid Ps.aeru S S S R S S S S S S R 
        51 1889 1 F NICU WI WS Ps.aeru S S S R S S S S S S R 
        52 1902 50 F Surgery WI WS Ps.aeru S S S R S S S S R R R 
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53 1910 32 M NICU VAP ET swabPs.aeru S S S R S S S S S S R 
        54 1918 54 M Surgery SSI Pus A.bau S S S S S S S S R R S 
        55 1924 57 F Surgery WI Pus A.bau R R S S S S S S S S S 
        56 1926 50 M Surgery WI Pus S.malt R R R R R R R S S S S 
        57 1936 45 M Surgery DM foot Pus S.malt R R R R R R R S S S S 
        58 1940 39 M ENT OE Pus Ps.aeru R R S R S S S S R R R 
        59 1944 50 M Burns Burns WS Ps.aeru R S R R R S S S R R R 
        60 2018 25 F OG WI Pus Ps.aeru R R R R R S S S R R R 
        61 2031 38 M Ortho OM Pus A.bau S S S S S S S S S S S 
        62 2036 45 F Surgery WI Pus Ps.aeru R R S R S S S S R R R 
        63 2046 30 F OG WI Pus S.malt R R R R R R R S S S R 
        64 2049 70 F Medicine Ascites As.fluid Ps.aeru R S S R R S S S R R S ESBL 
       65 2068 65 M Burns Burns WS A.bau S S S S S S S S S S S 
        66 2590 1 F NICU Sepsis Blood Ps.aeru R R S R S S S S R R R 
        67 2514 6 M Paed PUO Blood A.lwofi R S S R R S S S S S R ESBL 
       68 2001 40 M Medicine DM foot Pus A.bau S S S S S S S S S S S 
        69 2005 25 M Medicine Pneumonia Sputum Ps.aeru R R S R S S S S R R R 
        70 2008 24 M ENT OE Pus Ps.stut R R S R S S S S R R R 
        71 2574 6 M ENT CSOM Pus A.bau R R S S S S S S R R R 
        72 936 2 M PICU Pneumonia Sputum A.lwofi R R S S S S S S R R R 
        73 941 40 M Medicine DM foot Pus Ps.aeru S S S R S S S S R R R 
        74 942 50 M Burns Burns WS Ps.aeru R R S R S R S S R R R 
        75 961 66 M Surgery Pyothorax Pus A.bau R R R R R S S S R R R 
        76 985 26 F Surgery DMfoot Pus Ps.aeru R S R R R R R S R R R 
        77 1003 17 M Ortho #BBLL WS Ps.aeru R S R R R R R S R R R 
        78 1005 65 M Surgery DMCllulitis Pus A.bau S S S S S S S S S S S 
        79 1036 70 M Surgery Malig,SSI Pus A.bau S S S S S S S S S S S 
        80 1089 65 M Surgery SSI Pus A.bau R S S S S S S S R R S 
        81 2016 40 M IMCU Pl.effusion Pl.fluid A.bau R S S S S S S S R R S 
        82 2073 54 M Surgery SSI WS Ps.aeru R R S R S R R S R R R 
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83 6149 49 M Urology Pyelo Urine Ps.aeru R S R R R R R S S S R 
        84 2124 40 M Surgery Cellilitis Pus Ps.aeru R R S R S S S S R R R 
        85 3 65 M Surgery SSI Pus Ps.aeru R R S R S S S S R R R 
        86 15 65 M Surgery Dmfoot Pus Ps.aeru R R S R R S S S S S R ESBL 
       87 17 1 F PICU Pneumonia ET swabA.bau R R S R R S S S S S R ESBL 
       88 1924 57 F Surgery Abscess Pus A.bau R R S S S S S S R R R 
        89 1614 19 F Urology UTI Urine Ps.aeru S S S R S S S S S S R 
        90 449 47 M IMCU Empyema Pus Ps.aeru R R R R R S S S S S R 
        91 520 45 M Surgery  WI WS Ps.aeru R R S R S S S S R R R 
        92 7315 60 F SICU SSI Pus A.bau R S R R R R R S R R R MBL 64 
      93 542 22 F OG WI WS Ps.aeru S S S R S S S S R R R 
        94 559 68 M Surgery SSI Pus Ps.aeru R S S R R S S S R R R ESBL 
       95 569 45 F Surgery Crush injuryPus Ps.aeru R S R R R S S S R R R 
        96 595 21 M Medicine COPD Sputum Ps.aeru R R S R R S S S R R R ESBL 
       97 597 34 M TB ward Pneumonia Sputum A.lwofi S S S S R S S S R R R ESBL 
       98 1713 47 F Derm UTI Urine Ps.aeru S S S R R S S S S S R ESBL 
       99 505 1 M NICU Sepsis Blood A.bau R S R R R R R S R R R MBL 32 
      1001819 24 M Urology Pyelo Urine Ps.aeru R R R R R R R S R R R 
        101616 37 F OG WI Pus Ps.aeru S S R R R R R S S S R 
        1022076 55 M IMCU Empyema Sputum A.bau R S R R R R R S R R R MBL 32 
      1031125 50 M TB ward UL Cons. Sputum B.cep R R R R R S S R R R S 
        104910 31 M Burns Burns WS Ps.aeru R R S R S S S S R R R 
        105913 27 F Surgery SSI WS Ps.aeru R R R R R R R S R R R 
        1064848 3 M Paed UTI Urine Ps.aeru R R R R R R R S R R R 
        107914 37 M Burns Burns WS Ps.aeru R S R R R R R R R R R 
        108927 65 M Medicine Pneumonia Sputum B.cep R R R R R R R R R R S 
        1091207 45 M Medicine COPD Sputum B.cep R R S R R S S R S S S ESBL 
       1101109 40 F Surgery Abscess Pus Ps.aeru S S S R S S S S S S R 
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